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Abstract 
Background-aims: Circulating antibodies directed against self-antigens are a hallmark of several 
chronic diseases including autoimmune diseases and cancer. There is a growing need for the 
discovery of new autoantigens useful as biomarkers for the diagnosis, the prognosis and to guide 
therapeutic strategies. Here we present a high-throughput and unbiased approach to profile the 
immune responses in ovarian cancer as a model disease by identifying those tumor associated 
antigens (TAA) recognized by autoantibodies. 
Experimental design: Our technological platform combines a selection of a Phage display cDNA 
library followed by protein microarray and ELISA analyses of readouts and finally the correlation 
with clinical data.  As an initial step, we characterized ascitic fluids from patients for their antibody 
response respectively to soluble, insoluble intracellular proteins and cell surface expressed 
antigens present in an ovarian cancer cell line (OVCAR3). Secondly, the most reactive ascites 
were used in biopanning experiments, where an ORF cDNA phage library was screened in order 
to isolate ORFs recognized by antibodies present in those ascitic fluids. Further, hundreds of 
selected ORFs were produced as GST-fusion proteins and used to construct proteins microarray. 
These were tested with a set of ascitic antibodies from cancer patients. Candidate antigens were 
validated by ELISA screening on ascitic fluids from 153 patients that includes ovarian cancer 
patients, other cancer and non-cancerous controls.  
Result and discussion: We describe here an unbiased high-throughput (HT) approach to profile 
the ovarian cancer antibody repertoire. With this approach, we have identified and validated a set 
of different ovarian cancer specific IgG interacting tumor-associated antigens, which have 
significantly proven to correlate with patient survival. Moreover, we demonstrated the presence of 
autoantibodies in ascites targeting cell surface antigens expressed by tumor cells and its role in 
tumor regulation by activating the complement system.  
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Chapter 1 
1. Introduction 
1.1 Ovarian cancer  
Ovarian cancers are among the most lethal gynaecological malignancies worldwide. These cancers 
arise from ovaries which are a pair of almond-shaped female reproductive glands located on each 
side of the uterus and are responsible for generating ova (eggs) and the female sex hormones, 
estrogen and progesterone. The disease is characterized by few early symptoms, typical 
presentation at an advanced stage, and poor survival statistics. Depending on the kind of 
originating cells, cancer of the ovary can be sub-divided into three main types: epithelial ovarian 
cancer occurs in 80% of the ovarian cancer patients, gonadal stromal cancer in 5-10% and germ 
cell cancer in 10-15% of the patients (Fig. 1). This disease, produced by rapid growth and division 
of cells in the ovary ranges from benign to aggressive malignant and includes an intermediate class 
referred to as borderline carcinomas. In this chapter, an updated overview of ovarian cancer 
including diagnosis, screening and treatment strategy as well as the known potential biomarker for 
ovarian cancer are described. In addition, the role of high-throughput profiling techniques for the 
analysis of protein interactions and their importance in finding markers and targets for ovarian 
cancer therapy are discussed. 
 
 
Figure 1: Normal and cancerous ovaries. Types of ovarian cancer originated from different kind of cells of ovaries. 
[1] 
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1.2 Epidermiology of Ovarian Cancer 
Ovarian cancer is the seventh most common cancer among women with approximately 5900 new 
cases are diagnosis annually in Italy alone and over 238000 cases worldwide (Fig.2). Ovarian 
cancer is the leading cause of death from gynecological cancers in the Western world and is the 
eighth cause of death from cancer in women worldwide, accounting for more than 151000 deaths 
(as estimated by GLOBCAN 2012) [1]. Malignant tumors of the ovaries occur at all ages with 
variation in histological subtype by age. Germ cell tumors predominate in women younger than 
20 years of age, whereas borderline tumors typically occur in women in their 30s and 40s. 
Epithelial ovarian cancers, the most prevalent type of ovarian cancer usually occur after the age of 
50 years [2].  Ovary cancer rates are highest in women aged 55-64 years and the median age of 
patients diagnosed with ovarian cancer is 63 years. A woman's risk of getting ovarian cancer during 
her lifetime is approximately 1.43% (1 in 72). Her lifetime chance of dying from ovarian cancer 
is about 1 in 100, with a median age of 71 years at the time of death. Most women diagnosed with 
ovarian cancer are ethnically white and postmenopausal (approx. 55 or older). The relative five-
year survival rate women diagnosed with ovarian cancer, regardless of disease progression is 44.2 
percent. Survival rates vary depending on the stage of diagnosis. A 5-year survival rate of 92% 
can be attained, if the cancer can be diagnosed at its early stage when it is localized to ovaries. 
However, only 14.5% of ovarian cancer are diagnosed while the disease is confined to ovaries. 
The 5 year survival get drastically reduced to 27.3%  as the cancer advances and spread to the 
distant  organs (Cancer statistical data published by SEER Program of the National Cancer 
Institute) [3]. 
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Figure 2: Ovarian cancer Prevalence, Incidence, Mortality worldwide in 2012 [2]: A) worldwide 1-year prevalence 
proportions per 100000 females. It shows the number of persons across the world that have been diagnosed with 
ovarian cancer, and who are still alive at the end of a given year, the survivors. B) Incidence. C) Mortality caused by 
ovarian cancer across the world. An age-standardized rate (ASR) of incidence or mortality is the measure of the rate 
that a population would have if it had a standard age structure. 
1.3 Risk Factors in Ovarian Cancer 
The factors involved in the development of ovarian cancer are still largely unknown, but several 
risk factors, familial or not, have been described. A risk factor is something that may increase the 
chance of developing a disease. Studies have found the following risk factors for ovarian cancer: 
i) Age: The risk of developing ovarian cancer gets higher with age and increases dramatically in 
women over the age of 45 (median age at diagnosis of 63) [3].  
ii) Ethnic origin:  Most women diagnosed with ovarian cancer are ethnically white [3]. 
iii) Obesity: Obese women with a body mass index of at least 30 have a higher risk of developing 
ovarian cancer [4]  
iv) Reproductive history: Nulliparity is associated with an increased risk of ovarian cancer, 
whereas the risk goes down with each full-term pregnancy and breastfeeding may reduce the 
risk even further [5,6].  
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v) Birth control: Use of oral contraceptives decreases the chances of having ovarian cancer[5,6].  
vi) Gynecologic surgery: Women that underwent tubectomy or hysterectomy seems to reduce the 
risk of getting ovarian cancer considerably. 
vii)  Fertility drugs: Fertility drugs seem to increase the risk of the type of ovarian tumors known 
as "low malignant potential". 
viii) Estrogen therapy and hormone therapy: Some recent studies suggest women using 
estrogens after menopause have an increased risk of developing ovarian cancer. 
ix) Family history of cancer: Up to 10% of ovarian cancers are familial cancer. A family history 
of ovarian, breast or colorectal cancer is an important risk factor. 
x) Personal history of breast cancer: The risk of ovarian cancer after breast cancer is highest 
in those women with a family history of breast cancer. A strong family history of breast cancer 
may be related to the presence of an inherited mutation in one of two genes, known as BRCA1 
and BRCA2. These mutations can also cause ovarian cancer [4]. 
1.4 Etiology of Ovarian Cancer 
Although the causes of ovarian cancer are not well understood, there have been several hypotheses 
proposed regarding the cause of ovarian cancer. The “Incessant ovulation” theory postulated by 
Fathalla in 1971 suggested that a continuous cycle of damage and repair of the surface epithelium 
during ovulation increased the risk of developing mutation and their exposure to estrogen-rich 
follicular fluid may stimulate epithelium to malignant transformation. A number of findings have 
backed this hypothesis. Women with multiple pregnancies, increased time of lactation, and oral 
contraceptive use are associated with a reduced risk of ovarian cancer clearly correlates with 
decreased lifetime ovulatory events [6, 7].  
Later in 1975, Stadel proposed the “gonadotrophin” hypothesis for ovarian carcinogenesis. This 
hypothesis suggest in elevated levels of pituitary gonadotrophins promotes increased generation 
of estrogen or estrogen precursors, which are capable of stimulating the ovarian surface epithelial 
cells to undergo rapid cell division and produce malignancies [7-9].  
Toxic oxidants formed from inflammation or inflammatory reaction can cause direct damage to 
DNA, proteins, and lipids and may, therefore, play a direct role in carcinogenesis. Hence, 
inflammation may also provide biologic rationale for the increased ovarian cancer risk associated 
with talc and asbestos exposure, endometriosis, pelvic inflammatory disease, and mumps infection 
[7]. In 1997, Green et al. examined effect of tubal ligation and hysterectomy, which resulted in 
lower the risk of ovarian cancer. Thus, explained a theory that cancer-causing contaminants gain 
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access to peritoneal cavity through the vagina and pass through the uterus and fallopian tubes to 
reach the ovaries [7,10].  
Molecular alterations have been identified in a significant fraction of ovarian cancers. These DNA 
mutations that turn on oncogenes or turn off tumor suppressor genes can cause cancer upto a certain 
extent. 
1.5 Inherited genetic syndromes 
Studies suggest that 10% of all ovarian cancer cases have hereditary causes.  Several inherited 
genetic syndromes known to have association with a greater risk of developing ovarian cancer are 
been described.    
- Hereditary breast–ovarian cancer syndromes (HBOC) 
BRCA1 (chromosomes 17q) and BRCA2 (chromosomes 13q) are human genes that produce tumor 
suppressor proteins. These proteins are localized in the nucleus and are involved in DNA repair. 
Specific inherited mutations in BRCA1 and BRCA2 increase the risk of female breast and ovarian 
cancers. Women with a germ line BRCA1 mutation have a lifetime risk of 16% to 44%. While, 
mutation of the BRCA2 gene also increases the risk of ovarian cancer, but to a lesser degree with 
a lifetime risk is approximately 11-17%. Ovarian cancer associated with germ-line 
BRCA1 and BRCA2 mutations may tend to develop at younger ages than sporadic form of this 
disease [5,11].  
- Hereditary nonpolyposis colon cancer 
Hereditary non-polyposis colorectal cancer (HNPCC) syndrome (also known as Lynch syndrome 
II) is another familial disorder that carries with it an increased risk of ovarian cancer. This 
syndrome is caused by germline mutations in one of the five mismatch repair genes: MSH2 
(chromosome 2q), MLH1 (chromosome 3p), PMS1 (chromosome 2q) PMS2 (chromosome7p) and 
MSH6 (chromosome 2p) [4, 12]. The lifetime risk of ovarian cancer in women with HNPCC is 
about 12% with a mean diagnostic age of 42.5 years [13].  
- Li-Fraumeni syndrome 
Ovarian cancer is also a component of the rare Li-Fraumeni syndrome (LFS), which resulted from 
germline mutation and loss of TP53 function. It is one of the most frequent genetic abnormalities 
in ovarian cancer and is observed in 60–80% of both sporadic and familial cases [14]. TP53 
(chromosome 17p), encodes for a 53kd nuclear phosphoprotein that binds DNA and function as 
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tumor suppressor [15], negatively regulates cell growth and proliferation with damaged DNA 
leading to programmed cell death. A mutation in TP53 is directly correlated with a short-term 
survival benefit in ovarian cancer patients [16].  
- Cowden’s syndrome 
50-75% women of average age of 40 years with Cowden’s syndrome (also known as multiple 
hamartoma syndrome) develop breast or ovarian cancer or thyroid cancer. This inherited genetic 
disease caused again by mutations in the PTEN tumor suppressor gene (chromosome 10q23). This 
gene encodes a tyrosine phosphatase protein which effectively regulates cell proliferation [14, 17].  
- Peutz–Jeghers syndrome 
The Peutz–Jeghers syndrome (PJS) is an autosomal dominant polyposis disorder with very high 
relative and absolute risk for gastrointestinal and nongastrointestinal cancers, in which germline 
mutations in the STK11 tumor suppressor gene on chromosome 19p13.3 has been identified. The 
lifetime risk of ovarian cancer in women with PJS is estimated to be 21% [18]. 
1.6 Classification of ovarian cancer  
Ovarian cancer can be categorized mainly into three based on the origin of cells (Fig.3): A) Tumor 
developed from germ cells known as Germ cell tumor, B) Sex cord-stromal tumors from stromal 
cells or the connective tissue within the ovaries and which produces female reproductive hormones 
and C) Epithelial ovarian cancers or epithelial tumor of epithelial cells which cover the ovary. 
 
 
Figure 3: View of ovary at tissue level, includes Germ cells, Stromal cells and Surface epithelial cells or the surface 
cells [3] 
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Approximately 60% of ovarian cancer in young women 
nearly 20 years of age have originated from germ cell 
tumors. Most germ cell tumors are benign but some 
malignant cases have been reported. Common subtypes of 
germ cell tumors are teratomas, dysgerminomas, 
endodermal sinus tumors, and primary choriocarcinomas. 
Almost 5-10% of all ovarian cancer cases are effected by 
germ cell tumors [4, 9].Sex cord-stromal tumors account 
for approximately 10- 15% of all ovarian cancer cases. 
More than half of stromal tumors are found in 
postmenopausal women older than 50 and seen to occur 
in young girls to a lesser extent. Postmenopausal vaginal 
bleeding or precocious puberty due to production of 
female reproductive hormone (estrogen) by these tumors 
is one of the most common symptom. In rare cases, 
stromal tumor makes male hormone resulting in menstrual 
irregularities, hirsutism, and virilism. Common types of 
malignant stromal cell tumors include low-grade cancers 
such as granulosa cell tumors (most common type), theca 
cell tumors, sertoli-leydig cell tumors and hilar cell 
tumors (benign tumor) [4, 9].  
Epithelial ovarian cancers are the most common type of 
ovarian malignancies, causing more than 80% of all 
ovarian cancer cases. This type of cancer arises from 
ovarian surface epithelium and they can be either benign 
or malignant. Benign tumors are typically incapable to 
metastasize beyond the ovaries. There are several types of 
benign epithelial tumors including serous adenomas, 
mucinous adenomas, and Brenner tumors. Malignant 
tumors of the ovarian surface epithelium are known as 
carcinomas. These type cancers can spread to other parts 
Table 1: classification ovarian cancer [1] 
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of the body and can be fatal. Several tissue morphological features can be used to classify epithelial 
ovarian carcinomas into different types. i) Serous tumor, most common form and makes up to 40% 
of epithelial ovarian cancer cases. ii) Endometrioid tumors, the second most common type of EOC 
and comprising about 10-20% of EOC cases. iii) Clear-cell tumors accounts for 5-10%. While, iv) 
mucinous tumors make up approximately 1% of all of malignancies related to epithelium of ovary. 
v) Brenner tumors, mostly benign and less than 5% are proliferating or borderline constitutes 1.4-
2.5% of all ovarian cancer cases [9].  
If the morphology does not resemble any of the previous subtypes, these poorly differentiated 
tumor is called vi) undifferentiated tumors. Undifferentiated epithelial ovarian carcinomas tend to 
grow and spread more quickly than the other types. They are characterized as having low malignant 
potential that do not clearly appear to be cancerous. Approximately 15% of all EOC are 
undifferentiated tumors. vii) Mixed epithelial tumors are composed of 2 or more of the 5 major 
cell types of common epithelial tumors [9]. The list of ovarian cancer types are shown in Table 1 
Epithelial ovarian cancer may also be sub-classified by grading.  
• GX: Grade cannot be assessed.  
• G1: Well differentiated. 
• G2: Moderately differentiated.  
• G3: Poorly differentiated [2].  
 
1.7 Signs and Symptoms of Ovarian Cancer  
Early cancers of the ovaries often cause no symptoms. However, as the cancer progress, symptoms 
may include: 
 Bloating, a feeling of fullness, gas 
 Frequent or urgent urination 
 Nausea, indigestion, constipation, diarrhea 
 Menstrual disorders, pain during intercourse 
 Fatigue, backaches. 
It is highly recommended to consult a doctor if any of these symptoms last more than 2-3 weeks. 
A recent study conducted by Eltabbakh et. al suggest 78% of ovarian cancer patients  persisted  
with presenting symptoms. The most commonly reported symptoms includes abdominal or pelvic 
pain (35%), bloatedness (32%) and vaginal bleeding (20%) [19].  
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1.8 Screening Tests 
Screening tests are intended to detect early stage cancer in patients even before the onset of any 
symptoms. Identifying ovarian cancer in its early stages is very important because treatment is 
most effective while the disease is confined to the ovaries. Although there is no efficient screening 
test with a high sensitivity and specificity, the following available tests are recommended 
especially for those women with a family history of ovarian cancer. 
- Pelvic Exam: done to check the condition of ovaries and nearby organs for lumps or other 
changes in their shape or size [20].  
- Transvaginal Ultrasonography (TVUS): this imaging technique is another strategy to screen 
ovarian cancer. TVUS is enabled to detect changes in size and architectural features such as cystic 
features, solid features, septations, papillations, nodules, or free peritoneal fluid. This test is 
performed once with the development of any symptoms and with an abnormal pelvic exam. 
Transvaginal ultrasonography have been reported to possess the ability to differentiate benign from 
a malignant tumor by combining informations such as the size and the morphologic characteristics 
of ovarian masses [21].  
- CA-125 blood test: this test is approved by the Food and Drug Administration for screening 
women who are suspected for having ovarian cancer or abnormal pelvic exam. CA125 test 
measures the level of a protein tumor marker called CA-125 in patient’s blood. CA-125 - cancer 
antigen-125 (MUC16) is a glycoprotein which is overexpressed by ovarian cancer cells. A CA-
125 test result of titer greater than 35 U/ml is generally accepted as being elevated. Although the 
CA-125 blood test is more widely used to screen women for ovarian cancer, it can often be positive 
for reasons other than ovarian cancer (eg, endometriosis, fibroids, menstruation, ovarian cysts, 
pregnancy), thus reducing the specificity of the test. It is also not reliable early detection test for 
ovarian cancer. In about 20 percent of advanced stage ovarian cancer cases and 50 percent of early 
stage cases, the CA-125 is not elevated even though ovarian cancer is present. Generally, a better 
result can be obtained when CA-125 blood test used in combination with a transvaginal ultrasound. 
Currently, CA125 blood test is used to monitor the recurrence of ovarian cancer after treatment 
[20-25].  
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There are no recommended screening tests for germ cell tumors or stromal tumors. Some germ 
cell cancers release certain protein markers such as human chorionic gonadotropin (HCG) and 
alpha-fetoprotein (AFP) into the blood. After these tumors have been treated by surgery and 
chemotherapy, blood tests for these markers can be used to see if treatment is working and to 
determine if the cancer is coming back [4].  
1.9 Diagnosis  
Based on the results of the blood tests and ultrasound, a chest radiograph should be taken to screen 
for a pleural effusion while a computed axial tomography (CT) scan of the abdomen and pelvis 
should be performed to determine the extent of the disease. Depending on the factors such as age, 
symptoms, accumulation of ascites, elevated tumor markers, ultrasonographic data, CT findings, 
a suspected ovarian cancer patient undergoes surgery such as a pelvic laparoscopy or 
exploratory laparotomy. This involves a detailed examination of the contents, including all the 
peritoneal surfaces, ovaries, neighboring lymph nodes, other abdominal organs, omentum, surface 
of the diaphragm and all the suspicious sites. In addition, biopsy should be carried out for the histo-
pathological examination of the tissue or fluid to look for cancer cells. This initial surgery provides 
a definite diagnosis as well as the staging of tumor according to the size, extent, and location of 
the cancer [2, 20, 25].  
1.10 Staging of Ovarian Cancer. 
Staging describes where the tumor is located, or how far it has metastasized. Staging in ovarian 
cancer and other gynecologic cancers has been standardized by the International Federation of 
Gynecology and Obstetrics (FIGO). This system is currently been used by most gynecologic 
oncologists and which rely on the results of surgery for the actual stages. Stages are expressed in 
Roman numerals from stage I (the least advanced stage) to stage IV (the most advanced stage) [2].  
Stage I: Tumor confined to ovaries 
- Stage IA cancer has developed in one ovary, intact capsule, no tumor present on the surface 
of the ovary, no malignant cells in ascites or washings  
- Stage IB cancer has developed in both ovaries, intact capsule, no tumor on ovarian surface, 
no malignant cells in ascites or washings 
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- Stage IC one or both ovaries involved, ruptured capsule, tumor is on the outer surface of 
at least one of the ovaries, contains malignant cells in ascites or washings. However, the 
tumor has not metastasized to other organs 
Stage II: Pelvic extension 
- Stage IIA the cancer has spread to the uterus and/or the fallopian tubes, no malignant cells 
in ascites or washings 
- Stage IIB the cancer has spread to other nearby pelvic organs such as the bladder, the 
sigmoid colon, or the rectum, no malignant cells in ascites or washings 
- Stage IIC the cancer has spread to pelvic organs with all the features of stage IIA or IIB 
and contains malignant cells in the ascites or washings. 
Stage III: Peritoneal metastasis -Cancer spread beyond the pelvis to the lining of the 
abdomen and/or to lymph nodes   
- Stage IIIA cancer limited to the pelvis, microscopic implants on abdominal surfaces, no 
metastasis to the lymph nodes. 
- Stage IIIB abdominal implants but smaller than 2 cm in diameter and no metastasis to the 
lymph nodes. 
- Stage IIIC ovarian cancer has spread to lymph nodes, abdominal implants larger than 2cm. 
Stage IV: Distant metastasis beyond the peritoneal cavity- Cancer spread to the inside of the 
liver, the lungs, or other organs located outside the peritoneal cavity. 
Accurate staging is very important in determining a woman's long-term outcome (prognosis) and 
choosing the appropriate treatment regimen after surgery, since different prognoses at different 
stages are treated differently.  
1.11 Treatment  
Depending on the patient's age, stage and grade of the disease, the histopathologic type, and overall 
health, there are three main treatment options available for ovarian cancer. Primarily, surgical 
removal of the cancerous growth is the most common method of diagnosis and therapy for ovarian 
cancer, which is employed by a specially trained gynecologic oncologist. Chemotherapy uses 
anticancer drugs to kill cancer cells, and the third modality is radiation therapy, which is rarely 
used to treat ovarian cancer.   
Early diagnosed women with stage I ovarian cancer are mostly treated to cure by surgery and 
reported to have a five year survival rate of 90% [23, 24, 26]. Once ovarian cancer is confirmed, 
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surgery is performed which involves a total hysterectomy (removal of the uterus), bilateral 
salpingo-oophorectomy (removal of the fallopian tubes and ovaries on both sides), omentectomy 
(removal of the fatty tissue that covers the bowels), lymphadenectomy (removal of one or more 
lymph nodes). If the cancer has spread, an optimal debulking surgery is done to remove as much 
cancer as possible, leave behind no tumors larger than 1 cm. Most experts agree that optimum 
debulking ensued an improved survival rate in patients and helps to improve the patient’s response 
to chemotherapy [26]. 
Often, the treatments given in different combinations are more effective for treating advanced form 
of this disease. Surgical tumor debulking, followed by adjuvant chemotherapy is the standard 
treatment for advanced ovarian cancer. The typical course of platinum-based chemotherapy for 
epithelial ovarian cancer involves 3 to 6 cycles seems to be most effective  with a 5-year survival 
rate of 10-30% of women diagnosed with ovarian cancer at stage III or IV [27,28].  A combination 
of 2 or more drugs usually a platinum-based along with a taxane based compounds are used for 
chemotherapy. Debulking surgery followed by paclitaxel- carboplatin has become the ‘gold 
standard’ firstline treatment for ovarian cancer [28].  
Debulked epithelial ovarian cancer have shown a 20–30% improvement in both progression-free 
and overall survival when cisplatin was administrated intraperitoneal as primary chemotherapy 
when compared to intravenous delivery. Whereas, neoadjuvant chemotherapy followed by interval 
surgical cytoreduction produced a comparable result as primary debulking followed by 
chemotherapy in stages IIIC and IV disease [26,27].  
First-line chemotherapy, patients are clinically followed up for a period of 2-6 months where level 
of CA-125 have shown no survival benefits. Although 80% of the patients initially respond to 
platinum-taxane chemotherapy, most of these patients will develop recurrent disease. Progression-
free interval or the platinum-free interval (PFI) is the time from cessation of primary platinum 
based chemotherapy is now been widely used as the clinical surrogate for predicting response to 
subsequent chemotherapy and prognosis. Based on PFI, patients age is generally categorized into 
3 groups. Patients with a platinum free interval of more than 6 months are considered to be 
platinum sensitive and commonly treated with secondary cytoreductive surgery platinum based 
chemotherapy. Those which respond to primary treatment and relapse within 6 months are 
classified as platinum resistant and are treated with non platinum-based chemotherapy. Patients 
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who progress while on treatment or within 4 weeks of stopping chemotherapy are considered to 
be platinum refractory [2,26-28].  
By implementing novel treatment strategies for ovarian cancer may further improve the patient’s 
life expectancy. Targeted therapy is a newer approach that uses molecular targeted agents which 
specifically identify (cell receptors, signal transduction pathways, cell cycle regulators, angiogenic 
mechanisms etc) and kill cancer cells while doing little damage to normal cells.  
Bevacizumab is one of the most promising molecular targeted drugs in ovarian cancer. This 149-
kDa recombinant humanized monoclonal IgG1 anti-VEGF antibody was the first drug approved 
by the US Food and Drug Administration to target angiogenesis. VEGF and its receptors are 
essential for angiogenesis and are overexpressed in epithelial ovarian cancer. Bevacizumab 
monoclonal antibody inhibit the VEGF pathway by binding the VEGF ligand [27,29]. Recently, a 
couple of phase III trials in high risk or advanced ovarian cancer patients demonstrated that by 
giving carboplatin-paclitaxel plus bevacizumab as a first line treatment is able to prolong 
progression-free survival compared to standard carboplatin-paclitaxel alone [29,30].  
1.12 Biomarkers for Ovarian Cancer 
Biomarkers have been applied to the management of ovarian cancer in several different ways. 
These include monitoring response to treatment, distinguishing malignant from benign pelvic 
masses, estimating prognosis, predicting response to individual drugs, and detecting primary 
disease at an early stage. Among the biomarkers for epithelial ovarian cancer, CA125 has received 
the most attention to date. From the perspective of point-of-screening biomarkers, markers present 
in biological fluid have a great potential in detecting early stage of ovarian cancer. Recent 
developments in genomic and proteomic research have identified a number of candidate 
biomarkers in the management of ovarian cancer. They can be used for global screening purposes 
would enhance preventative cancer care at an early stage of ovarian cancer as well as to monitor 
the clinical follow up. Some of the potential biomarkers for the purpose of early detection and 
screening ovarian cancer are listed in table 2 with a high diagnostic and prognostic value [24, 31-
35]. Table 3 shows the potential diagnostic-prognostic biomarkers identified in 1990s to present 
which can be used for diagnostic purposes but are not currently used in the clinic.  
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Diagnostic biomarkers for ovarian cancer  
Marker Full name Localization Description 
• CA125 
• HE4 
• Prostasin 
• IAP 
Cancer antigen 125 
Human epididymis protein 4  
Prostasin 
Immunosuppressive acidic protein 
Serum 
 
 
 
 
 
 
Stage-nonspecific biomarkers: diagnosis & 
follow-up 
• hK6,7 
 
• HNF‑1β 
• WT-1 
human kallikrein 6 
human kallikrein 7 
hepatocyte nuclear factor (HNF)‑1β 
Wilms tumor 1 
Tissue 
 
• TGF-α 
• uAS 
• Mesothelin 
Transforming growth factor alpha 
Urinary angiostatin 
Mesothelin 
Urine 
 
• CKB Creatine kinase, brain Serum & tissue Tumor stage-specific biomarkers: early 
stage 
• TP 
 
Thymidine phosphorylase Serum & tissue Tumor stage-specific biomarkers: later 
stages 
• CLIC4 
• VSGP/F-Spondin 
Chloride intracellular channel 4 
Vascular smooth muscle growth promoting 
factor 
Tissue 
 
Tumor stage-specific biomarkers: later 
stages 
• IAP Immunosuppressive acidic protein Serum 
 
Tumor stage-specific biomarkers: later 
stages Screening of ovarian cancer relapse 
 
Prognostic biomarkers for ovarian cancer 
Marker Full name Localization Description 
• hK8 human kallikrein 8 Serum  
Prognostic: 
favorable 
• hK13 
• hK11 
• PR 
human kallikrein 13 
human kallikrein 11 
Progesterone receptor 
 
Tissue 
 
• hK10 
• IGFBP-2 
• YKL-40 
• tPA 
human kallikrein 10 
Insulin-Like Growth Factor Binding Protein 2 
Chitinase-3-like protein 1 
Tissue plasminogen activator 
 
Serum 
 
 
 
 
 
 
 
Prognostic: 
unfavorable 
 
• αv β6 integrin 
• α-V integrin 
• β III tubulin 
• CD24 
• c-Ets1 
• EMMPRIN 
• GEP 
• Indoleamine 2,3-dioxygenase 
• M-CAM 
• p-glycoprotein 
• Topoisomerase II 
• WT-1 
αv β6 integrin 
α-V integrin 
β III tubulin 
CD24 molecule 
c-Ets1  
Extracellular matrix metalloproteinase inducer 
Granulin-epithelin precursor 
Indoleamine 2,3-dioxygenase 
Melanoma cell adhesion molecule 
p-glycoprotein 
Topoisomerase II 
Wilms tumor 1 
 
 
 
 
 
 
Tissue 
 
Table 2: Diagnostic and prognostic biomarker for ovarian cancer: List of potential biomarkers for the purpose of early 
detection and screening ovarian cancer [2]. 
 
Ovarian Cancer Diagnostic-Prognostic Markers  
Marker 
 
Full name Diagnostic/ 
prognostic 
Localization Description 
B2M  β2-microglobulin Diagnostic Serum Suitable tool to monitor course of  disease when 
used in combination with  CA125 
CA54/61  
 
Mucin-type glycoprotein 
antigen 
Diagnostic Serum In case of mucinous cystadenocarcinoma 
Sensitivity 65% (compared with 36% of CA125) 
CA72‑4  
 
 
Cancer antigen 72‑4/ 
TAG‑72 
Monitoring/ 
diagnostic 
 
Serum/tissue Discriminates negative serous adenomas from 
positive serous carcinomas 
CA125 II  Cancer antigen 125 II Diagnostic Serum More precise than CA125 
CA602  
 
Cancer antigen 602  Diagnostic Serum 100% sensitivity in serous adenocarcinoma 67% 
of sensitivity in mucinous adenocarcinoma 
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caGT  
 
 
Cancer-associated 
galactotransferase antigen 
Diagnostic  Serum 8/9 in clear cell carcinoma 
Cathepsin B  
 
Cathepsin member B Preoperative 
differential 
diagnosis 
Serum Serum level is fairly proportional to 
FIGO stage; serous > endometroid 
tumors (p < 0.001) 
CD34  CD34 molecule Prognostic Tissue Blood vessel count related to lower overall 
survival (p = 0.022) 
COX-1  Cyclooxygenase-1  Diagnostic Serum Serum level is proportional to tumor progression 
GAT  
 
Glyphosate N-
acetyltransferase 
Diagnostic Serum Differential diagnosis from endometriosis 
IAP  
 
Immunosuppressive 
acidic protein 
Diagnostic Serum Early detection of recurrence 
M-CSF  
 
Macrophage 
colonystimulating factor 
Diagnostic Serum Serum level is useful in detecting ovarian cancer 
nm23-H1  
 
Non-metastatic cells 1, 
protein (NM23A) 
Prognostic Tissue Inverse association with 
metastatic potential 
TP53  
 
Tumor protein p53  Prognostic Tissue p53 expression related to 
unfavorable prognosis 
Progesterone  Progesterone  Diagnostic Serum Mainly related to nonendocrine ovarian 
tumor volume 
Sialyl SSEA-1 
antigen 
Sialyl SSEA-1  
 
Diagnostic/ 
prognostic 
Serum Fair Differential diagnosis with other markers 
TNF receptor  
 
p75/p55  Diagnostic Ascitic fluid Proportional to peritoneal fluid quantity and stage 
of disease 
HOXB7 Homeobox7 Diagnostic Serum Their expression have found to promote growth 
and development of ovarian carcinomas 
SIK3 Salt-inducible kinase 3 Diagnostic Ascitic fluid promotes G1/S cell cycle progression when 
overexpressed and cytoplasmic localization 
specifically in the tissue obtained from ovarian 
cancer patients 
Osteopontin Osteopontin Diagnostic Serum Their presence in higher levels were found in the 
serum of patients with epithelial ovarian cancer, 
including early stage disease 
LPA Lysophosphatidic acid Diagnostic Ascite fulid Elevated total LPA levels were detected in the 
plasma of 80% of early stage ovarian cancer 
patients 
VEGF Vascular endothelial 
growth factor 
Diagnostic Ascite fulid/ 
serum/ tissue 
A panel of five markers that included VEGF 
could detect ovarian cancer with a sensitivity of 
84% at 95% specificity 
IL-6 and IL-8 Interleukin 6 and 8 Diagnostic  A combination of 5 markers including IL6, IL8 
and CA125 achieved a sensitivity 84%  and a 
specificity of 95% for early stage disease. 
STAT3 Signal Transducer 
and Activator of 
Transcription 3  
Prognosis  Tissue  Expression of phosphorilated STAT3 form is 
increased in primary ovarian cancer and its 
nuclear localization is associated with a poor 
prognosis 
LPAAT-β LPAAT-β enzyme Prognosis  Tissue/serum  An increase of enzyme expression has been 
correlated to a poor prognosis and is associated 
with a minor survival 
MMP Matrix metalloproteinase  Prognosis Tissue/serum In stromal cells, high levels of MMP-2, MMP-9 
MT1-MPP, (a subgroup of no soluble enzymes, 
connected to cellular 
membrane) are linked to a poor prognosis in 
patients with EOC. 
MIF Macrophage migration 
inhibitory 
factor 
 Serum  Higher levels of serum  
MIF were found in ovarian cancer patients with 
sensibility of 77,8% and specificity of 53,3% 
Table 3: Potential ovarian cancer biomarker currently not used in clinics [3]. 
Due to the fact of the complex nature of the pathogenesis and of the tumor-host interaction in 
ovarian cancer, several studies relied to use a panel of markers on multiplex platforms. This 
permits simultaneous analysis of multiple markers with very small volumes of serum. 
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Mathematical techniques have been incorporated to discover many combinations of marker levels 
to high sensitivity and improve specificity for early-stage disease (Table 4). This however requires 
prospective validation [24, 32-34,36].  
 
Panel of biomarker for ovarian cancer 
Marker Panel Sensitivity (%) Specificity (%) 
CA125/IL-6/IL-8/VEGF/EGF 84 % 95% 
CA125/IL-6/G-CSF/VEGF/EGF 86.5 % 93% 
Leptin/Prolactin/Osteopontin/IGF2 95 % 94% 
Leptin/Prolactin/Osteopontin/IGF2/MIF/CA125 95.3 % 99.4% 
CA125/HE4/Glycodelin/PLAUR/MUC1/PAI-1 80.5 % 96.5% 
CA125/  
HE4/ 
 Mesothelin 
78%  
68-82% 
31-44% 
98% 
CA125/ CA19- 9 /EGFR /CRP/Myoglobin/APOA1/APOC3/MIP1A/ IL-
6/IL-18/Tenascin C 
91.3 % 88.5% 
CA-125/OVX1/M-CSF 84% 84% 
CA125/M-CSF/ OVX1/ LASA/ CA15–3/ CA72–4/CA19–9 and CA54/61 94.3% 90.9% 
CA125/ CA72–4/ CA15–3 and LASA 79% 87.5% 
CA125/ HE4/ sEFGR/  sVCAM-1 90% 98% 
Table 4: Panel of Biomarker: Different combinations of ovarian cancer biomarker producing varying range of 
sensitivity and specificity [4]. 
2. Ascitic Fluid 
Ascites is the excess accumulation of fluid in the peritoneal cavity. The term derives from the 
Greek word askites, meaning bag-like. It is caused by many pathologies including malignancy 
which accounts for 10% of all ascite formation. While ovarian cancer alone accounts for 38% of 
malignant ascites occurring in women during the course of their disease. Malignant ascites are 
capable to develop secondary and distant metastasis such as breast, liver, lungs or other organs 
located outside the peritoneal cavity [27,37-39].  
Malignant cells secrete proteins, cytokines, growth factors such as vascular endothelial growth 
factor (VEGF), vascular permeability factor (VPF), and matrix metalloproteinases (MMPs) play 
an important role in the malignant ascites formation, metastasis and influence the aggressiveness 
of neoplastic cells. They are responsible for neovascularization, angiogenesis and an increased 
vascular permeability of small blood vessels. These together with lymphatic obstruction by tumor 
invasion are the main factors leading to an increased production and accumulation of ascitic fluid 
in the peritoneal cavity (Fig 4) [37-39]. Newer strategies to prevent the formation of ascites, 
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including anti-vascular endothelial growth factor (VEGF) therapy, are proving promising to 
overcome platinum resistance in ovarian cancer [27, 29, 38,39].  
 
 
 
Figure 4: Pathophysiology of malignant ascite. a) Peritoneal cavity of a normal healthy person and the peritoneal 
membrane covers the visceral organs, as well as the abdominal and pelvic cavities. b)  In patients with tumors in the 
abdominal cavity, the cross-sectional area of microvessels lining the peritoneal cavity is increased, and this results in 
an increased filtration surface for fluid. In addition, malignant ascites has a high protein concentration that is secondary 
to increased capillary permeability. Inflammatory cytokines and chemokines, as well as reduced lymphatic flow, all 
contribute to alterations of the peritoneal membrane. These changes decrease the plasma to peritoneal oncotic pressure 
difference, so the direction of flow of fluid is into the peritoneal cavity. This leads to the build up of pathological 
volumes of fluid in the peritoneal cavity [4].  
 
Malignant ascites typically comprised of variable proportions of suspended cells that includes 
tumor cells, mesothelial cells, fibroblasts, macrophages, white blood cells, red blood cells and 
debris depending on the pathogenesis. 37% lymphocytes, 29% mesothelial cells, 32% 
macrophages and less than 0.1% adenocarcinoma cells have been reported to be present in ascitic 
fluid collected from ovarian cancer patients [38, 40]. In addition, ascitic fluid contains secreted 
proteins, antibodies against the proteins or peptides secreted or leaked from tumor tissue, soluble 
growth factors that have been associated with invasion and metastasis, and chemokines are present 
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[41-43]. Thus making ascitic fluid an excellent reservoir to study various biological aspects of the 
underlying tumor and equally important for the identification of prognostic and predictive 
biomarkers and for molecular profiling analysis of various tumors including ovarian cancer.  
2.1 Complement System in Ascitic Fluid. 
The complement (C) system is an essential component of innate and adaptive immunity. It plays 
an important role as cytotoxic effector arm for both immunological surveillance in the host defense 
against infectious pathogens and mAb-therapy. The complement system consists of some 30 
soluble molecules / proteins synthesized locally by many cell types, including macrophages, 
fibroblasts and endothelialcells and several neoplastic cells. The components of this system in 
circulating blood plasma can easily reach the tumor site and diffuse inside the tumor mass is an 
advantage over other effector systems. Most of these protein components of the complement 
cascade are activated upon cleavage by a protease, which leads to each component's becoming, in 
its turn, a protease. Three pathways are involved in complement attack upon pathogens: i) classical 
pathway ii) alternative pathway and iii) mannose-binding lectin pathway (MBL -MAPS). These 
results in the release of chemotactic factors and cell-activating anaphylatoxins (C3a, C4a and C5a), 
deposition of opsonic fragments and formation of the membrane attack complex (MAC) [44,45]. 
It was also evident from previous studies that the deposition of c components in various tumor 
masses indicative of complement activation and its subsequent pathogenetic effects [46,47].  
L Bjørge et al investigated complement system in ascitic fluid from ovarian cancer patients. The 
characterization revealed that most of these ascitic fluids were involved in the haemolytic activity 
either by alternative and classical pathway. While, the lack of MAC on the malignant cells isolated 
from the ascite samples was probably due to the expression of C membrane regulators on the tumor 
cells.  The higher concentrations of soluble forms of C1 inhibitor and the alternative pathway 
inhibitors however did not affect the capability of ascitic fluid causing complement mediated 
killing of ovarian carcinoma cells. They also described the utility of C system as an effector 
mechanism in therapy with intraperitoneally administrated mAbs, especially if the intrinsic C 
regulators are neutralized [48-50].  
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3. Proteomic Technology for the Study of Diseases 
Ovarian cancer has been referred to as very complex and heterogeneous. Because of this, tumors 
with the same histological features that arise in different patients may display diverse alterations 
with different patterns of oncogene activation or tumor-suppressor gene loss, thus complicating 
determination of the importance of an individual gene's alteration. Currently, many genomic tests 
used to diagnose ovarian cancer or guide its therapy do not decrease women's risk of dying from 
this disease or do not improve their quality of life (QoL) [24,179,180].  
Over the past decade, high-throughput technologies has stimulated their use in many bio-medical 
applications. In this field, proteomics has emerged as a powerful technology providing a central 
opportunity for the rapid identification and development of novel detectable biomarkers as well as 
tumor-associated antigens. It denotes the large-scale characterization of proteins, including 
complicated features like isoforms, modifications, interactions, and functional structures. Large 
varieties of proteins are known to be produced by the cancer that can be identified in the biological 
fluids of patients. Thus, protein biomarkers may be more specific in respect to cancer type and 
status than gene-based biomarkers. For diagnostic applications, protein-based biomarkers in body 
fluids provide easy-access as well. 
In cancer biomarker discovery, various methods like two dimensional gel electrophoresis, mass 
spectrometry (MS), and protein microarrays as well as combination of different technology as a 
single platform such as serological proteome analysis (SEPRA),  serological analysis of 
recombinant cDNA expression libraries (SEREX), phage display  have become powerful tools to 
identify proteins markers. These methods could be used to study differential expression of 
hundreds and thousands of protein simultaneously. However, each approach has strengths and 
limitations.  
Two-dimensional gel electrophoresis is a traditional approach that separates proteins according to 
two distinct protein characteristics, size and charge [181]. The usefulness of this approach was 
demonstrated in past studies to differentiate ovarian cancer sample proteome from healthy controls 
[182,183]. In recent years, improvements were made to overcome the major drawbacks of 2DE by 
the introduction of fluorescent two dimensional differential in-gel electrophoresis (2D-DIGE). 2D-
DIGE facilitated accurate protein separation, detection, and quantitation and hence became an 
important tool for biomarker discovery of cancers, including ovarian cancer [184]. The main 
disadvantage these 2DE is that they are highly vulnerable to reproducibility and comparability. 
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 Mass spectrometry (MS) is one among the major technique widely used for the discovery of 
cancer biomarkers, which can determine the precise mass and charge of proteins, and thus identify 
the actual precursor proteins or protein profiles. There are two basic approaches to utilize these 
data for early detection of ovarian cancer. One method attempts to identify a distinctive signature 
or pattern of protein expression that distinguishes healthy individuals from cancer patients. 
Surface-enhanced laser desorption and ionization (SELDI) or matrix-enhanced laser desorption 
and ionization (MALDI) have been used to detect novel patterns of low-molecular-weight moieties 
in ovarian cancer sera from all stages with controls. SELDI patterns have reported a sensitivity of 
95% or more at 95% specificity for early detection of ovarian cancer [185]. The second approach 
employs SELDI to identify putative markers proteins and peptides that provide the greatest 
discriminatory power and develops individual bioassays to analyze each protein [186]. However, 
mass spectrometry technology have some limitations, while they are used for protein profiling of 
complex diseases such as ovarian cancer, as the data are difficult to reproduce and that they may 
be biased by artifacts in sample preparation, storage and processing, and patient selection [187]. 
Another proteomic based approach Serological Proteomics Analysis (SERPA) took advantage of 
combining the classical 2-DE with Western blotting to screen patient sera for autoantibodies 
against cancer specific antigens, and it precedes a further step involving MALDI–TOF MS 
analyses, which identifies the nature and abundance of the total proteins in sample analyzed. The 
group of Francesco Novelli have successfully demonstrated the utility of this technique to 
prediction early stages of pancreatic ductal adenocarcinoma (PDAC) by detection of 
autoantibodies against Ezrin [188]. In general, limitations of detecting autoantibodies by SEPRA 
arise from the inherent limitations of 2-DE. Those are the potential loss of small (<15 kDa), very 
large (>200 kDa), very acidic (pI < 3), very basic (pI > 10) and very hydrophobic proteins as well 
as the inability to detect TAA with conformational epitopes due to the denaturing conditions. 
Whereas both phage display system and SEREX utilizes cDNA libraries for the expression and 
detection of antigens that elicit a humoral immune response in patients. To this end, mRNA 
extracted from appropriate tissue or cell line is converted to cDNA by in vitro methods and 
subsequently cloned into a bacteriophage for infection of Escherichia coli (E. coli). Contrasting to 
phage display system, SEREX adopts a lytic infection of the host bacteria; the recombinant 
proteins are expressed and can be blotted onto a nitrocellulose membrane for antibody screening 
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with sera. Seroreactive proteins can then be identified by sequencing the phage cDNA from 
positive plaques. SEREX has been useful for identifying several tumor specific antigens that 
generate a humoral immune response in cancers such as those from the kidney, lung, breast and 
colon [189, 190]. Likewise, SEREX immunoscreening was utilized to identify a set of novel tumor 
antigens that are associated with ovarian cancer and may prove useful for the early detection and 
treatment of this disease [191,192]. 
As underlined before, the great advantage of such approach stays in the fact that conventional 
methods require the preparation of a large number of membrane filters to be screened and that 
patients sera are usually available in limited quantity. Phage display technology permits the 
enrichment of reactive proteins by selection with very small amounts of serum, leading to a low 
number of clones to be screened. In general, the combination of SEREX-based techniques (that, 
although useful, in its original form presents severe methodological limitations) with novel tools, 
allowing the creation of large functional libraries, ensuring the ability to manage them with the 
appropriate systems, and integrated with innovative techniques for the sensitive and specific 
detection of analytes of interest, would represent a major breakthrough in this field of study. ORF 
selection, phage display, protein arrays, new proteomic technologies, and so on, are all suitable 
candidates for the development of these new integrated systems. The reports on the use of these 
technologies in profiling ovarian cancer are limited. 
4. Expression Library  
Expression library represents an important approach for the study of the expression profiles of 
biological systems. This methodology provide a direct physical association between the protein 
under analysis and the gene encoding these proteins. Expression cDNA libraries are the most 
common source of DNA for screening approaches. They offer valuable strategy for the 
identification of disease markers, new therapeutics and targeting agents for focused therapy. They 
are prepared from total single-strand mRNA extracted from whole organisms such as yeast or from 
various tissues, encompassed of greater variety of genes that are specifically expressed. Later, this 
isolated mRNA is converted into double-strand DNA copy (cDNA) by means of reverse 
transcriptase enzyme. Once cloned into an appropriate plasmid, the final population of 
recombinant vectors obtained represents the entire set of genes expressed by the source of starting 
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mRNA. Various formats are used for expression of eukaryotic proteins; of them bacterial system 
is most favorable one for its ease of use and high yield of protein. Although eukaryotic systems, 
such as the baculovirus system [52,53], can also be used. 
cDNA or genomic DNA libraries can be used in many different applications such as PCR, DNA 
hybridization [54], two-hybrid systems [55], enzymatic activity [56], high-throughput structure 
determination [57] and by recognition with antibodies. This study focus on its application to 
identify tumor associated antigens (autoantigens) which specifically recognizing immunoglobulins 
present  in ascitic fluid from ovarian cancer patients, and will be discussed in detail in chapter 2.  
To this end, with an intention to enhanced expression and exposition (in display systems) of 
polypeptides, fragmented cDNA libraries are preferred. cDNA can be fragmented by means of 
physical methods (sonication), chemical or enzymatic methods (DNase) [58] and PCR-based 
methods [59]. Fragmented cDNA libraries increase chance to identify restricted binding sites and 
epitopes. Moreover, high degree of heterogeneity among the polypeptide sequences can be 
achieved.  
It is important to enrich the library for potentially reactive proteins, in order to limit the number of 
proteins to be screened. These results in the need for: a) a system to remove non functional DNA 
sequences from the library, to decrease the library size; b) a system to select proteins of interest 
from the high original complexity. Both problems could be overcome by ORF selection systems 
and display/selection techniques described in section 4.5 of this chapter. 
 
5. Display systems  
Display technology refers to a collection of methods for creating libraries of modularly coded 
biomolecules that can be screened for desired properties in a high-throughput format on a global 
scale.  This innovative approach has facilitated large-scale analyses of protein–protein/protein–
substrate interactions, rapid isolation of antibodies (or antibody mimetics) without immunization, 
and function based protein analysis. The concept of expression library can be readily applied to 
the display systems: by means of recombinant DNA technology, wide collections of different 
particles displaying polypeptides can be generated and through specific selections strategies, 
providing a progressive enrichment of such complex libraries based on their specific reactivity. 
Two main advantages of this system are: first, the selected protein can be immediately 
characterized and identified by a simple DNA sequencing reaction; secondly, the gene encoding 
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the protein of interest can be manipulated with all the tools provided by molecular biology and 
genetic engineering techniques. Thus, allowing isolation and identification of specific proteins and 
related genes from a background of billions of unreactive clones [63].   
There are three main formats or display platforms:  
i) Peptide-on- DNA/RNA display: These are cell-free display systems where DNA or RNA are 
capable to bind its own coded peptide. Thus, permitting a screening of a large pool of complexes 
and identify the interactors by isolation and sequencing of nucleotide sequences of either DNA or 
RNA.  
ii) Viral (Phage) display: It is one of the most commonly used display system. Here the gene of 
interest is cloned into the coding sequence of viral coat proteins and expressed as fusion with a 
surface protein of the phage. These fusion protein exposed on the surface of the phages allows the 
selection and isolation of novel interactors for its binding property to a given protein from a 
collection of billions of phages. Several different viral systems have been used to display peptides, 
including lysogenic filamentous phages, and lytic lambda phage, T7 bacteriophage, and T4 
bacteriophage. We have employed this approach using filamentous phage for our study and will 
be described in much depth. 
ii) Cell based display:  Here the cDNA library encoding various proteins is recombinantly 
expressed in cultured cells and selected for binding to a specific ligand on the cell surface. Yeast 
two hybrid system is the most popular among this category due to the high efficiency of 
transformation. 
5.1 Phage Display 
Phage display is a system for the high throughput analysis of protein interactions by selecting 
peptides, proteins, or antibodies with specific binding properties from a pool of variants. This 
technique uses bacteriophage for the coupling of phenotype to genotype. Here, cDNAs libraries 
from appropriate tissue sources are expressed as fusion proteins with one of the phage coat proteins 
and exposed on the surface of the phage. Thus, allowing the selection and isolation of novel 
interactors for its binding property to a given protein from a collection of billions of phages [64-
70]. Characterization by DNA sequencing to identify these unknown interacting proteins is 
relatively easy and straightforward step.  
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The concept of displaying proteins or peptides or polypeptides on the surface of filamentous M13-
derived bacteriophage (phage) was first introduced by G.P. Smith in 1985 [71]. Smith 
demonstrated that phages could be manipulated in their genome level by inserting a foreign DNA 
into the gene encoding phage coat protein, retaining their infectivity and displaying a specific 
fusion protein on its surface. These fusion proteins in their immunologically accessible form could 
be isolated for its binding property by biopanning against immobilized immunoglobulins thereby 
enabling over a 1000 fold enrichment of the epitope binding sites of the antibodies. 
Depending on the particular application, many types of phage have been used for phage display 
including Ff filamentous phage, Lambda and T7. The Ff filamentous phage family (M13 and its 
close relatives fd and fl) have been widely adopted since they provide a robust and highly flexible 
platform for display. Among them, filamentous bacteriophage M13 have been used as the source 
of the majority of successful screenings and best characterized library display vector by far [72,73]. 
M13 is a filamentous bacteriophage contains a circular single stranded DNA (6407 base pairs long) 
encapsulated by approximately 2700 copies of the major coat protein pVIII and capped by five 
copies each of pVII and pIX at distal end. While, the proximal end is composed of four to five 
copies each of pVI and pIII. (Fig. 5)  The protein pIII has been identified as the one responsible 
for phage infection and for release of the phage particle following assembly. It has two N-terminal 
domains (N1 and N2) and a C-terminal domain (CT). Infection of E.coli host is mediated by the 
interaction between phage coat protein pIII through its N2 domain (one of the two N-terminal 
domains of pIII) and the F-pilus. This in turn, brings TolA protein (a membrane protein in E. coli) 
into close proximity and interacts with N1 (second N-terminal domains of pIII), leading to the 
deposition of phage circular ssDNA into the cytoplasm and later converted to dsDNA bacterial 
enzymes. The C-terminal domain of pIII known as ‘CT’ terminates phage assembly in the 
periplasm and release phage from the cell membrane. These filamentous phage infected E.coli 
cells do not get lysed, instead they replicate and are released from the cell membrane without 
killing the host as in contrast to Lambda and T7 [74].  
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Figure 5: M13 filamentous bacteriophage displaying fusion protein [5]. 
 
Although all five M13 phage coat proteins have been demonstrated to be utilized, mostly pIII 
followed by pVIII and rarely pVI are used for phage display with respect to the number of fusion 
proteins displayed per phage and stability of the fusion proteins. Three different types of phage 
display exists by far that includes a) phage system, b) hybrid system and c) phagemid system (fig 
6).   
Generally, in phage system, the insert DNA are cloned upstream to the gene encoding the pIII or 
pVIII and are present as a single copy. A large numbers of smaller proteins (upto 2700 copies) 
may be displayed if pVIII is chosen as a fusion partner. Whilst pIII efficiently displays a fewer 
numbers of larger proteins [72,73,75].  
In Phagemid system, the virion contains the phagemid that carries an antibiotic resistance marker, 
bacterial and phage origins of replication, the phagemid DNA containing a phage promoter 
upstream of the sequence encoding the fusion protein which is to be displayed, and a phage 
packaging signal. The transformed bacteria with this phagemid are later infected with packaging-
defective helper phage providing all the proteins necessary for phage assembly.  Infection with 
helper phage initiates the assembly preferably using phagemid DNA carrying a fully functional 
packaging signal. Thus, drives the expression of fusion library on phage coat proteins and carry 
the phagemid encoding that sequence. In hybrid system, the phage genome contains two copies of 
phage coat protein gene, one with a fusion partner and a wildtype. Specially designed promoters 
for these two genes allows a higher expression of wildtype as compared to the fusion protein 
[72,76].   
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Figure 6. The three types of phage display. (A) Phage systems. The phage genome contains only one copy of pIII 
(black), and the displayed sequence (white) is fused to that copy. Consequently, every pIII displays the same fusion 
protein (triangle). (B) Phagemid systems. Instead of a phage genome, the virion contains the phagemid, which is 
generally smaller. Infection with helper phage drives the expression of phage proteins, and the phagemid expresses 
the pIII fusion library.  (C) Hybrid systems [6].  
 
5.2 Phage display Selection 
Unlike the other conventional immunoscreening approaches, phage display technique is much 
faster as well as more cost and labour effective, requiring no special equipment. Once a phage 
display library has been constructed, successive rounds of selection based on affinity selection 
permits the enrichment and isolation of less abundant interacting proteins from a library with large 
diversity. Selection strategy generally involves the following steps (Fig. 7):  
 
1. Library amplification and phage particle production  
2. Enrichment by immunoprecipitation of phage particle with immobilized target. 
3. Washing step to remove the unbound phages  
4. Elution and amplification of bound phages by infecting host bacteria. 
These biopanning rounds are repeated aleast three to six times to achieve a sufficient enrichment 
of binding peptides. The selected peptides are then identified by sequencing their corresponding 
DNA [75,76].  
 
Introduction 27 
 
 
 
 
 
Figure 7: Phage display selection cycle. Binding protein selection from phage display libraries. Step 1: Libraries of 
proteins are displayed on phage particles as fusions to coat proteins. Each phage displays a unique protein and 
encapsulates the encoding DNA. Highly diverse libraries (>1010) can be represented as phage pools. Step 2:  Antigen-
specific clones can be selected by binding to immobilized antigen followed by step 3: washing to remove nonbinding 
phage.  Step 4: Retained phage can be amplified by infection of a bacterial host, and the amplified pool can be cycled 
through additional selection rounds to further enrich for antigen-binding clones. Individual binding clones can be 
subjected to DNA sequencing to decode the sequences of the displayed proteins [7]. 
 
5.3 Application of Phage display 
5.3.1 Identification of protein-protein interactions in vitro 
Over 80% of cellular proteins may work in complexes with other proteins and their protein–protein 
interactions are regulated by several mechanisms [63,77]. Phage display has been employed in 
numerous studies of protein-protein interactions. Peptide libraries have been used to determine the 
epitope to which an antibody binds [78]. Various strategies including genomic scale screening by 
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construction of fragmented whole genome and gene fragment phage display libraries allowed an 
in-depth characterization of the protein region involved in the interaction [79]. 
Phage display have also proved as a useful tool in mapping the interacting domains of the binding 
proteins. For instance, this technique was used to map protein-protein interaction sites  between c-
myb proto-oncogene product and its coactivator CBP [80]. Again, Fuh et al in 2000 successfully 
demonstrated the carboxyl-terminal phage display as a powerful new method for mapping PDZ 
domain binding specificity [81]. Phage libraries were used to identify the structural motifs 
recognized by major histocompatibility (MHC) molecules and could be used to determine the 
binding motifs of other MHC class II alleles and isotypes [82].  
The capability of this approach is not limited to protein or peptide interactors, phage display have 
been reported to be used in identifying binding proteins for non-protein molecules like 
phosphatidylserine [83]. The possibility of using phage display technique in identifying protein-
DNA interactions was well highlighted in the work done by X.Cheng et al. [84]. Carbohydrate-
protein interaction is an important process in cell to cell recognition. Peptide phage display 
biopanning facilitated a positive selection of carbohydrate binding peptide [85]. In addition, Wang 
et al. 2003 demonstrated its usefulness to isolate the peptides interacting with carbon nanotubes 
[86]. Human bcl-2 was identified as the binding partner of a small chemical compound taxol using 
phage display [87].  
Phage display has been used in enzymology to determine their substrate. Novel peptide inhibitor 
of the enzymatic activity of Human kallikrein 2 (hK2), a serine protease was identified by 
screening their exposed enzymatically active site of the enzyme against phage display peptide 
library. These peptides are potentially useful for treatment and targeting of prostate cancer by 
modulating pathways involving hK2 [88]. Using a combination of phage display selection and 
highthroughput screening methods, Wirsching and colleagues generated variants of hirudin, a 
thrombin-specific inhibitor, with increased protease resistance that may prove useful for 
hematologic disorders [89].  
5.3.2 Phage display selection on live cells 
Over the past decade, approaches to efficiently select phage libraries against molecules expressed 
on cultured cells and mouse and human tissues have evolved. Selection on living cells can be done 
on either monolayers of adherent cells or on cells in suspension. The basic procedure involves the 
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removal of unbound phage by washing and phage recovery is done by bacterial infection. In a 
study conducted by Doorbar et al, human platelets were used directly as targets for the selection 
of a peptide antagonist of the thrombin receptor [90].  
In 2001 Giordano and colleagues described a new approach for the screening, selection and sorting 
of cell-surface-binding peptides from phage libraries. Biopanning and rapid analysis of selective 
interactive ligands (BRASIL) allows separation of complexes formed by the cells and bound phage 
from the remaining unbound phage still in the suspension. This method is based on differential 
centrifugation in which a cell suspension incubated with phage in an aqueous upper phase is 
centrifuged through a non-miscible organic lower phase. The same group further evaluated this 
approach by screening human endothelial cells stimulated with vascular endothelial growth factor 
(VEGF), constructed a peptide-based ligand-receptor map of the VEGF family and validated a 
chimeric ligand-mimic that binds specifically to VEGF receptor-1 and neuropilin-1 [91]. More 
recently, phage display selection approach was successfully applied to in vitro co-culture model 
of human umbilical vein endothelial cells (HUVECs) and gastric adenocarcinoma cell line resulted 
in the identification of peptides targeting vascular endothelial cells in gastric cancer [92].  
5.3.3 In vivo phage library selection 
This technique involves intravenous administration of a phage-displayed random peptide library 
into animals and letting them to circulate for a certain period of time to allow distribution of the 
clones.  Then organs or tissues are collected and examined for phage bound to tissue-specific or 
differentially expressed disease markers.  This method was first described by Pasqualini and his 
colleagues in 1996, to isolate peptides that are capable of mediating selective localization of phage 
to brain and kidney blood vessels in vivo [93]. This approach was latter used to isolate peptides 
recognized by the repertoire of circulating tumor-associated antibodies purified from the serum of 
prostate cancer patient [64]. Many more studies have used this technique to identify receptors for 
peptides homing to the vasculature of the lung, breast [94], placenta, white adipose tissue, 
pancreas, muscles, intestines, uterus and other organs. The first in vivo screening of a peptide 
library in human was introduced in 2002 by Arap et al [95].  
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5.3.4 Antibody phage display 
Phage display of antibody fragments has been used successfully in generating target specific 
antibodies which can be useful in multiple applications including proteomics, specific drug 
delivery and in analysis of intracellular processes. The major advantages in using phage display is 
for generating antibodies with high affinity, specificity  and stability which is completely 
independent in its nature for not immunizing any animals, especially humans and uses an in vitro 
selection process [96]. During the past decade, phage display library screening techniques have 
been developed to isolate monoclonal antibodies (mAbs) for therapeutic applications. Human 
antibody, Adalimumab (tradename Humira) a human IgG1 specific for human tumor necrosis 
factor (TNF) was the first fully human antibody used for clinical practice is an example of such 
antibodies approved for therapy [97-101]. 
5.4 Recent innovations in phage display technology 
Several noticeable developments on phage display application to map protein-protein interactions 
were eventually implemented. Selectively-infective phage (SIP) is a novel methodology for the in 
vivo selection of interacting protein-ligand pairs. This is a method that eliminates the need for 
physical separation of specific and unspecific binders, therefore providing an efficient and rapid 
procedure for selection of high-affinity interactions [102]. Bacteriophage vectors have potential as 
more efficient gene transfer and vaccine delivery vectors because of their low cost, safety and 
physical stability. The attractive features offered by this system have paved the way for various 
attempts to develop phage as a vector for gene therapy applications [103- 106]. Another important 
advancement is their feasibility to use phage display technology for targeted chemotherapy to treat 
cancer [107].  
4.5 Selection of Open Reading Frames 
In such complex library, apart from cloned genes that encodes protein, there are large number of 
non-functional clones present. Eliminating out-of-frame DNA sequences has become desirable, 
and sometimes even essential for an increasing number of applications in protein engineering and 
genomics. Pre-screening a library to remove frame-shifted variants is an effective way to reduce 
the amount of molecular diversity to be assessed in subsequent steps, while simultaneously 
enriching for useful diversity and therefore increasing the probability of identifying a clone with 
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the desired function. The concept of filtering DNA for the presence of open reading frames (ORFs) 
was necessarily introduced to the library we used for this study (Fig 8). Most innovative among 
all filtering approach was to clone DNA fragments upstream of the β-lactamase gene in an 
appropriate vector and clones produced were selected for ampicillin resistance. This ORF enriched 
library was then digested or filtered based on Cre-lox mediated recombination by replacing β-
lactamase gene with another gene (like phage coat protein gene) encoding  ORF as their fusion 
partner [60, 61,178]. While these systems have proven efficient at removing frame-shifted library 
members, they also inevitably impart selection pressure for the folding and solubility of the protein 
of interest, and as it is impossible to quantify the degree of selection pressure for folding imparted 
by the existing systems, the risk is that functional variants will be eliminated in the course of 
preselection for reading frame. Systems have been described also for open reading frame selection 
without a prerequisite for the folding and solubility [62]. 
 
 
 
Figure 8: Schematic representation of ORF filtering: Random fragments are cloned upstream of a β-lactamase gene. 
Those fragments that are ORFs permit readthrough into the β-lactamase gene and confer ampicillin resistance. Those 
that are out of frame, or contain stop codons, do not survive. After selection on ampicillin, the β-lactamase gene can 
be removed by passage through bacteria expressing Cre recombinase. The selected ORF can then be displayed on 
phage [8]. 
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5.6 Phage display for cancer biomarker  
Expression library screening especially phage display of cDNA libraries from appropriate tissue 
sources has proved to be a useful strategy for identification and isolation of novel interactors. They 
have been relied for studies of many different cancer types including ovarian cancer. Here, the 
selection involves biopanning of a phage display library using immunoglobulins purified from 
biological fluids (such as serum or ascitic fluid) of an ovarian cancer patient as bait. Thus, allowing 
the identification of autologous antibodies targeting tumor antigens as a sensitive biomarker. There 
are limited number of reports on the use of these technologies in ovarian cancer of them most 
marked ones are described (Table 5). 
Honami Naora and colleagues utilized phage display screening to isolate and identified tumor 
antigen encoded by the homeobox gene HOXB7.  An up-regulation of HOXB7 expression was 
found to promote growth and development of ovarian carcinomas [108]. In 2004, Claudia I Vidal 
et al described methodology where antibody fingerprinting is a combinatorial screening in which 
phage display random peptide libraries are selected on in vitro pools of immobilized ascitic 
immunoglobulins from ovarian cancer patients. They identified  the heat-shock protein 90 kDa 
(HSP90) as the native antigen mimicked peptide and evaluated their immune response is restricted 
to a subset of patients with advanced disease [109]. Later, Chatterjee et.al.  used a combination of 
high-throughput phage display selection and protein  array based serologic  detection of many 
potential antigens and validated autoantibodies present in the sera of patients as biomarkers for 
ovarian Cancer. Forty-five unique antigen biomarkers where found to solely interact with ovarian 
cancer patients IgG but not with patient having benign gynecologic syndromes. These includes 
some known antigens, RCAS1, signal recognition protein- 19, AHNAK-related sequence, nuclear 
autoantogenic sperm protein, Nijmegen breakage syndrome 1 (Nibrin), ribosomal protein L4, 
Homo sapiens KIAA0419 gene product, eukaryotic initiation factor 5A, and casein kinase II, as 
well as many previously uncharacterized antigenic gene products having a known or suspected 
association with cancer. The experiment resulted in an average sensitivity of 55% and specificity 
98% with all the identified antigens. While, an average sensitivity and specificity of 32% and 94% 
respectively was resulted from the top 6 of the most specific clones [110]. More recently, an in 
vitro screening approach by phage display library was used to isolate a novel peptides ZP1 
(sequence SVSVGMKPSPRP) which specifically bound to its target human ovarian tumor cell 
line SK-OV-3 and therefore suggests its potential for targeted drug delivery in ovarian cancer 
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therapy [111]. In the same year, S.Charoenfuprasert et.al identified salt-inducible kinase 3 (SIK3) 
as a TAA through screening of a random peptide library in the phage display system.  This novel 
ovarian TAA promotes G1/S cell cycle progression when overexpressed and shown to have a 
cytoplasmic localization specifically in the tissue obtained from ovarian cancer patients. Clinical 
study on this antigen resulted in survival advantages to cancer cells for growth and correlates the 
clinicopathological conditions of patients with ovarian cancer [112].  
 
Technique Antigen Source (cDNA 
Library) 
Autoantibody Source TAA Ref 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phage 
Display 
Human ovarian cancer cell line Serum HOXB7 [108] 
Random peptide library Ascite HSP90 mimic peptide [109] 
Human ovarian cancer cell line Serum RCAS1 
Signal recognition protein-19 
AHNAK-related sequence 
NASP 
Nijmegen breakage syndrome 1 
Ribosomal protein L4 
Homo Sapiens KIAA0419 gene product 
Eukaryotic initiation factor 5A 
Casein kinase II 
Chromodomain helicase DNAbinding protein 1 
[110] 
12-mer phage 
display random peptide library 
Human ovarian 
tumor cell line.   
to isolate cell surface-
bound peptides binding 
specifically to SK-OV-3 
cells 
 
SVSVGMKPSPRP [111] 
Random peptide library Ascite SIK3 [112]  
 
Table 5: Biomarker for ovarian cancer identified by phage display [5] 
 
 
6. Protein Microarray  
Protein arrays provide a powerful tool to examine interactions between proteins (including 
antibodies), peptides, DNA/RNA or chemical compounds on a large scale. Here, such arrays would 
contain collections of microscopic analyte spots at high density usually between 500 up to a million 
different proteins are immobilized in an orderly manner to a solid surface. Further, by applying 
conventional hybridization processes, expression levels or interaction events are measured [113].  
There are three general types of protein array (Fig 9):  
i) Functional protein microarrays, constructed by immobilising large sets of purified proteins or 
an entire proteome are screened for a wide range of biochemical functions, such as protein-protein, 
protein-DNA, protein-small molecule interactions and enzyme activity, and to detect antibodies 
and demonstrate their specificity. It comprises protein/peptide/antigen microarrays.  
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ii) Analytical microarray,  where primarily antibodies, antibody mimics, affinity reagents, but may 
also be nucleic acid aptamers are arrayed and used to evaluate the presence and concentrations of 
proteins in a complex mixture such as plasma/serum or tissue extracts. It comprises antibody 
microarrays. 
iii) Reverse-phase microarrays employ the complex samples such as tissue lysates are printed on 
the surface (the bait) to capture antibodies (the prey). In the case of lysates from cancer tissue or 
cell lines as source of the bait, proteins require liquid phase fractionation, incorporating isoelectric 
focusing and reverse-phase liquid chromatography (LC), prior to printing onto an array support. It 
comprises lysate microarrays. 
 
 
 
 
Figure 9: Types of protein microarrays and their possible applications. a) Protein microarrays (PMAs), consisting of 
individual recombinant proteins; b) antibody microarrays (AMAs), consisting of antibodies or fragments; and c) 
reverse protein microarrays (RPMAs), consisting of whole or fractionated protein lysates/extracts. All the three types 
of arrays are screened for their ability to bind with known or putative directly labeled interaction partners [9].  
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6.1 Protein microarray production 
There are several concepts to be taken into consideration when manufacturing or analyzing a 
protein array. 
6.1.1 Printing methods 
To generate protein microarrays, materials have to be spotted or deposited at defined xy 
coordinates onto the substrate of choice, generally a glass slide which has been modified or coated 
in some manner. This process has to be highly precise (± 2 μm) and robotics are typically used to 
transport solutions from sources (e.g., 384 well plates) to slides. The amount of solution deposited 
per spot is typically a few nanolitres and thus 10μL of a solution will provide sufficient material 
for over 2000 chips or microarrays. The fact that such tiny amounts of material are required is one 
of the major advantages of microarrays. Protein microarray production is typically achieved in one 
of these ways: contact printing [114,115], inkjet and bubble-jet printing [116,117], piezoelectric 
[118], electrospray deposition [119], photolithograpy [110-112]. All these systems provide 
environmental controls, which includes temperature and humidity as well as maintaining all 
parameters such as contact time, distance between spots etc. 
6.1.2 Protein immobilisation considerations, formats and surfaces 
The right choice of the proper substrate is important when setting-up a protein array system. There 
are some crucial feature that are needed to be fulfilled while choosing a slide. The best surface 
requires optimal binding conditions to conserve the protein functionality during immobilization 
enabling protein in their correct orientations and maintaining their three-dimensional structural 
conformation. A high binding capacity with low unspecific background to accommodate proteins 
of varying composition will be an advantage [123]. To meet the requirements of protein 
microarrays, several surfaces have been proposed, which can be divided into three major groups 
as shown in table 6 [124] 
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Table 6: Different types of protein microarray surfaces [6] 
 
6.1.3 Detection methods 
The detection methods available to detect interactions are generally depend on the microarray 
format and substrate. They are basically divided into two: i) Labelled probe method: they are 
conventional methods that usually use fluorescent, chemioluminescent, colorimetric or radioactive 
detection. Fluorescence is used primarily for its high sensitivity and excellent dynamic range to 
produce quantitative results [125,126]. ii) label-free methods, including mass spectrometry (MS) 
[127], surface plasmon resonance (SPR) [128], atomic force microscopy (AFM) [129], 
microelectromechanical systems (MEMS) [130] and quartz-crystal microbalance analysis (QCM) 
[131]. Although label-free detection technologies are highly desirable, their availability and 
sensitivity have not been high enough to have come into common use for functional protein 
microarrays. Many new strategies have been developed, in particular to achieve higher levels of 
sensitivity. For example, Rolling circle amplification (RCA) generates a localized 1000 fold higher 
fluorescent signal via amplification of an oligonucleotide circle carried by the secondary antibody 
[132, 133].  
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6.2 Applications of Microarray 
All array types have uses in diagnostics (biomarkers or antibody detection) and discovery research. 
Protein microarrays allow the detection of specific antibodies in biological fluids such as serum or 
ascitic fluid against a very large number of targets simultaneously. Typically, a complex mixture 
would be applied to arrays of possibly thousands of specific binders, and the individual bound 
analytes detected in parallel by appropriate labelling and scanning. In proteomics, array can be 
used for expression profiling to compare the levels of proteins in different samples. Arrays can 
also be used as high throughput platform to determine patterns of antigens recognized by 
autoantibodies during the course of diseases, such as autoimmunity or cancer, as well as a way to 
characterize the repertoire, so called ‘autoantibody signatures’ that may represent disease subgroup 
or to monitor immune responses in healthy individuals. Here, the samples to be analysed 
themselves will find their target depending on the binding properties and screened for cross 
reactivity against many proteins, which can also be done in a multiplex array format against 
multiple protein targets. 
6.3 Application of protein array in discovery of autoantigens in cancer 
In the field of oncology, protein arrays offer huge potential as tools for the identification of cancer 
biomarkers, in particular auto-antibody/antigen markers. The identification of tumor associated 
antigens (TAAs) recognised by the patient's immune system represents an exciting approach to 
identify novel diagnostic cancer biomarkers and to contribute towards a better understanding of 
the molecular mechanisms involved. Circulating autoantibodies have not only been used to 
identify TAAs as diagnostic/prognostic markers but to determine their potential as therapeutic 
targets (Table 7). In a study conducted by Xiaoju Wang et al, identified a panel of 22 phage derived 
peptides was identified, discriminating autoantibody signatures in prostate cancer compared to the 
control group with a sensitivity of 88.2% and 86.1% specificity. Autoantibodies against peptides 
derived from prostate-cancer tissue could be used as the basis for a screening test for prostate 
cancer [134]. Tumor-associated antigen arrays represent an excellent platform to profile 
autoantibody for the enhanced detection of early stages of tumors and permit monitoring of the 
efficacy of treatment [135].  
In earlier studies of Gil Mor et. al reported to identify 4 serum protein  markers for early diagnosis 
of ovarian cancer. A combination leptin, prolactin, osteopontin, and insulin-like growth factor-II 
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initially analyzed by microarray and eventually these potential biomarkers were evaluated by 
ELISA, as alone as well as in combination. Finally evaluated with a different cohort and analyzed 
by multiple statistical approaches in a blind manner and resulted in sensitivity of 95% and 
specificity 95% when used in combination. They claimed to discriminate between a healthy and 
EOC patients, including patients diagnosed with stage I and II disease, with high efficiency (95%) 
[132].  
In a similar study conducted by M A Hudson et al in 2007, used protein microarray (V3.0, 
Invitrogen) with 5005 human proteins to identify proteins aberrantly expressed in ovarian cancer 
when probed with sera from various stages of ovarian cancer patients. Lamin A/C, SSRP1, and 
RALBP1 were found to be candidate tissue markers and exhibit an increased expression in the 
cancer tissue relative to controls when immunostained. Suggesting, these are useful marker for 
biopsies but not for routine screening of fluid samples from patient [136]. Later, C.G Gunawardana 
and colleagues used protein microarray technology to identify autoantibody signatures in ascitic 
fluid collected from ovarian cancer and fifteen potential tumor-associated antigens were 
discovered. Among all, AASDHPPT showed the strongest signal-to-noise ratio [126].  
Conversely, Gnjatic and colleagues used a commercially available protein microarray (V4.0, 
Invitrogen) with 8277 human proteins to identify autoantibodies in ovarian cancer and pancreatic 
cancer sera. Of the arrayed proteins, 202 proteins demonstrated a greater immunoreactivity and 
stronger fluorescent signal in ovarian cancer patient sera compared to 29 in pancreatic cancer, with 
few overlaps. They also determined correlates of autoantibody signatures as potential good or bad 
prognostic antibody responses against different combination of antigens [125].  
More recently, array defined autoantibody reactivity towards nucleophosmin, cathepsin D, p53, 
and SSX were identified as common antigens for patients at each stage (I–IV) of ovarian cancer 
were significantly higher than for controls  when compared to healthy or benign ovarian disease. 
Furthermore, mean autoantibody level against placental-type alkaline phosphatase, TAG 72, 
survivin, NY-ESO-1, GRP78 and Muc16 (CA125) was significantly different and allowed the 
differentiation between Stage III/IV and early stage ovarian cancer [137].  
The success rates of phage display methods were critically improved with the introduction of 
protein microarray screening as concluding steps of phage selection. Here, selected phage derived 
proteins were arrayed on slides and immunoscreened by protein microarray to identify antigens 
specifically recognized when challenged with patient samples. These recent developments permit 
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a drastic reduction in the large collection of protein derived from phage expression systems and to 
focus on several hundred to a few thousand which were identified with high potential and validate 
these in larger cohorts of patients using protein arrays. This was very well demonstrated in a study 
to identify autoantibody signature in prostate cancer [134]. In 2006, Chatterjee et.al successfully 
used this same approach to evaluate the potential of a large panel of tumor antigens as biomarkers 
for a serum-based screening test that can detect the presence of epithelial ovarian cancer. The 
author also describes this as a global approach to antigenic profiling, epitomics, has applications 
to cancer and autoimmune diseases for diagnostic and therapeutic studies [110]. 
As summary, protein microarrays are suited for detecting autoantibody responses. Moreover, their 
ease of use, the low amounts of reagents and sample required and the number of molecules that 
can be tested per array make them ideal for multiparametric testing. 
 
Technique Array Format Autoantibody 
Source 
TAA Ref 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein 
Microarray 
169 protein in RCA 
Microarray 
Serum leptin, prolactin, osteopontin, and insulin-like 
growth factor-II 
[132] 
protein microarray (V3.0, 
Invitrogen) with 5005 human 
proteins 
Serum Lamin A/C, SSRP1, and RALBP1 [135] 
ProtoArrays® Invitrogen Ascitic fluid L-aminoadipate-semialdehyde 
dehydrogenasephosphopantetheinyl 
transferase  (AASDHPPT) 
[126] 
V4.0, Invitrogen) with 8277 
human proteins 
Serum 202 Autoantigens [125] 
Phage derived Peptide/protein Serum RCAS1 
Signal recognition protein-19 
AHNAK-related sequence 
NASP 
Nijmegen breakage syndrome 1 
Ribosomal protein L4 
Homo Sapiens KIAA0419 gene product 
Eukaryotic initiation factor 5A 
Casein kinase II 
Chromodomain helicase DNAbinding protein 1 
[110] 
Ovarian cancer cell line 
(exosome derived) dot blot 
array 
Serum Nucleophosmin, cathepsin D, p53, SSX 
Placental-type alkaline phosphatase, TAG 72, 
survivin, NY-ESO-1, GRP78 and Muc16 (CA125) 
[137] 
Table 7: Autoantigens in ovarian cancer identified by Protein Microarray.
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7. Rationale of the project  
Ovarian cancer is the fifth most common cancer among women and is major causes of death from 
gynaecologic cancer. Each year, approximately 238000 (3.7% incidence of all cancer cases) new 
cases of ovarian cancer were diagnosed worldwide (as estimated by GLOBCAN project in 2012) 
accounting for more than 151000 (4.3% of all cancer mortality) deaths in women [1].This is due 
to the lack of reliable and effective early detection methods, since majority of early-stage of these 
cancers are asymptomatic and are detected at later stages, after they have invaded the surrounding 
tissues [23]. Most often, metastasis of ovarian cancer occurs through the cells which they shed into 
the peritoneal cavity. Since there is no anatomical barrier exist in peritoneal cavity, these tumor 
cells metastasize once they are embedded/implanted to peritoneal surface and advance to pelvic 
organ (Stage II), the abdomen (stage III) or beyond the peritoneal cavity (stage IV) [14,21] . Only 
25% of ovarian cancers are diagnosed in the early stage (Stage I) while they are confined to the 
ovaries. Up to 90% of stage I ovarian cancer patients can be cured by currently available therapy. 
The cure rate become narrowed down to less than 20% when diagnosed at an advances stages of 
this cancer [23]. These numbers mentioned above clearly support the need for new efficient 
biomarkers for early diagnosis.  
Although the diagnosis, treatment and survival of this heterogeneous, genomically unstable and 
highly lethal disease in women is based on clinical features such as tumor size, histological 
subtypes, FIGO stage, differentiation grade and the presence of genetic markers (Such as BRCA1 
mutations)  or  proteins markers in biological fluids. The response to the treatment greatly varies 
among the patients even though they presents similar clinical features. The major detection 
approaches for ovarian cancer includes transvaginal ultrasonography (TVUS), serum markers and 
a combination of the two [21]. Cancer antigen-125 (CA-125) is the most extensively investigated 
and currently been used for the serum based screening of epithelial ovarian cancer (EOC). 
Although CA-125 is well characterized tumor biomarker specific to EOC, they have a limited 
ability to detect early stage of this disease and hence used to monitor the effectiveness of the 
treatment [138,139].  
In past years, studies have revealed the presence of circulating autoantibodies specific to a number 
of tumor-associated antigens (TAAs) in human [64,140]. These tumor-associated antigens absent 
in a normal cell may elicit a very early host immune response in course of tumor development, 
this feature could be made use to develop biomarkers which can detect autoantibodies which are 
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stable and abundant even at the early stage of tumor [110]. Thus, identification of these TAAs 
could leads to the discovery of important molecular pathways involved in the development of 
ovarian cancer, and may give insights regarding the onset of tumorigenesis and therapeutic 
strategies. Moreover, TAAs has been already demonstrated to be an effective and sensitive means 
of cancer screening and diagnosis [112]. Using TAAs as biomarker for cancer could be superior 
of choice, since they are capable of measuring varying level of immune response in reasonably 
short time. Despite from all these advantages, these TAAs can be used for targeted 
immunotherapeutic treatments and might require for vaccine development in the far end of this 
study [65]. Very few tumor-associated antigens have been identified to-date, offering a promising 
area yet to be explored. 
Accumulation of ascitic fluid in peritoneal cavity is a characteristic feature of ovarian cancer. Since 
it remain in closer or direct contact with the disease site, ascetic fluid is an optimal source 
containing secrete proteins, antibodies against these secreted or leaked proteins or peptides from 
tumoral tissue, soluble growth factors that have been associated with invasion and metastasis. Thus 
making ascitic fluid an excellent reservoir to study various biological aspects of the underlying 
tumor and equally important for the identification of prognostic and predictive biomarkers and for 
molecular profiling analysis of various tumors including ovarian cancer. To date, there exist no 
systematic analysis to characterize ovarian carcinoma ascites. 
The recent advance in the field of discovery technologies made it possible to profile molecular 
signature in any autoantibody/autoantigen related pathologies including cancer and autoimmune 
disease simultaneously during the progress of the disease. In this study, we utilized a combination 
of technologies that combines phage display selection and immunoscreening protein microarray 
allowing a highthroughput analysis of a large set of analyte.  Our laboratory have already 
demonstrated the usefulness of this approach in the identification of molecular targets in various 
autoimmune diseases [141]. An extensively characterized cDNA phage library was used in this 
study consists almost every genes present in the human genome. More information about the 
library is described in the result section of this thesis. To this extend, we applied our technological 
platform for the high-throughput profiling of ovarian cancer ascites with an intention to overcome 
the difficulty to detect their molecular targets or tumor antigens, which are present in lower 
abundance and consequently increased the specificity to a few fold magnitude.  
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8. Objective of the research 
After completion of the sequencing of the human genome, scientists shifted their attention to the 
products of the genome, the proteins, in the hope of development of personalized medicine and 
diagnosis. The term “proteome” was coined as a linguistic equivalent to the concept of “genome”; 
it is used to describe the entire set of proteins expressed by genome of the cell, tissue or an 
organism at a particular time or throughout the lifetime. The proteome is highly dynamic by nature 
with complex molecular system that requires accurate methodologies to study the interactions 
between this large numbers of components and which is referred to as the “proteomics”. Advances 
in proteomic technologies allow the large-scale determination of gene and cellular function 
directly at the protein level in a highthroughput format. The field of proteomics is a collection of 
various technical disciplines, leading to a sensitive analysis of complex interactions network such 
as those established during the immune response [142]. 
 
With the intention to profile ovarian cancer antibody repertoire in a systematic manner, we propose 
a novel approach by combining different technological platform which enables the identification 
of the interactors/molecular signature of disease from a high degree of complexity and present in 
low abundance with high sensitivity. In addition, to determine the clinical implications of 
identified interacting antigen specifically expressed by tumor cells as a prognostic tool to predict 
the cancer survival. The key steps involved in highthroughput profiling of ovarian cancer ascitic 
fluid are: 
 
- Characterize ascitic fluid collected from various disease conditions based on their antibody 
response against antigens present in ovarian carcinoma cells. 
- Isolation and identification of immune reactive antigen  
- Validation of the novel antigen and their clinical correlation  
- Surface targeting antibody and CDC mediated regulation of tumor growth 
 
 
 
Project Summery 43 
 
 
 
9. Project Summery  
In this study, we present a systematic and in-depth profiling of ovarian cancer ascites. Thus, to 
isolate and identify the antigens recognized by ovarian carcinoma ascites antibodies. In addition, 
to validate and evaluate these selected antigens for their clinical correlation in the disease. The 
ascites represents an optimal source for molecular profiling of ovarian cancer. We ranked ascitic 
fluid for its reactivity by characterizing them for their antibody response against cellular antigens 
in ovarian cancer.  The most reactive ascites were chosen for further investigation. To this extent, 
we utilized a highthroughput protein expression and screening platform that combines cDNA 
phage display library selection and proteins microarray approach were used to profile ascitic fluids. 
Phage libraries of open reading frame (ORF) fragments created from mRNA derived from various 
tissues were used. Here, cDNAs are expressed as fusion proteins with one of the phage coat 
proteins and exposed on the surface of the phage thus allowing the selection with antibody present 
in ascites collected from ovarian cancer patients, which were identified as most reactive [64-69, 
108-112]. Successive rounds of biopanning allowed the patient antibodies to select their own ideal 
binding peptide and isolation of these less abundant interacting proteins from a library with large 
diversity. Phage display selected peptides were further screened for their immunoreactivity by 
protein microarray analysis. Further, microarray identified antigens were validated by indirect 
ELISA, since these immunological techniques are able to detect the presence of specific antibody 
even at very low concentration [143]. Subsequently, correlates of autoantibody signatures with 
known tumor expression of corresponding antigens, prognostic value and patient survival outcome 
were examined. Moreover, we demonstrate the presence of autoantibody in ascites targeting cell 
surface antigens expressed by tumor cells and determined its role in controlling tumor growth by 
activating complement system. 
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Chapter 2 
10. Results  
10.1 Introduction to results 
To date, there is no systematic analysis of the antigens recognized by ovarian carcinoma ascites 
antibodies. To address this issue we designed a comprehensive discovery and validation strategy, 
outlined here (Fig 10):  
1) cDNA library construction from human tissues: The cDNA is filtered to retain only 
clones encoding Open Reading Frame (ORF) fragments which are then displayed on 
filamentous phage. 
2)  Characterization based on autoantibody response: This involves an  initial examination 
of the ascites from cancer patients using tissue culture cells or their extracts as source of 
antigens in Western blotting, whole cell ELISA, cell lysate ELISA assay and by indirect 
immunofluorescence on whole cells. With these immunotechniques, we identify ascites 
which have high-titer fluorescent staining or strong signals to cell extracts and 
subsequently use the purified antibodies to isolate ORF displaying Phages.  
3) Selection of immunoreactive antigens: Phages displaying proteins are 
immunoprecepitated with ascites antibodies from ovarian cancer patients through cycles of 
selection and amplification.  
4) Immunoscreening by protein microarray: Putative antigens are cloned and expressed as 
GST-fusion proteins and immunoscreened by independent sets of cancer and control 
antibodies by protein microarray.  
5) ORF sequencing: The antigens, screened by protein array were identified by sequencing.  
6) Validation by ELISA:  ELISA was performed to determine whether the antibodies present 
in the ascitic fluid from the ovarian cancer patients were specifically recognized by the 
selected peptides derived from the screenings.  
7) Clinical correlation: Clinical correlation of overall survival of the patients with the 
presence of specific antibodies against the identified novel antigens was determined. 
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Figure 10: Workflow of the project. 1) construction of cDNA library from appropriate tissue or cells followed by 
filtration of cDNA to retain only clones encoding Open Reading Frame (ORF) fragments which are then displayed on 
filamentous phage. 2) Characterization of ascitic fluid base on the autoantibody response against ovarian carcinoma 
cellular antigens. 3) Most reactive ascites antibodies were used for phage display selection to immunoprecipitate the 
interacting peptides displayed on filamentous phages. 4) Protein microarray approach to immunoscreen a large set of 
phage-selected peptides expressed as fusion protein simultaneously with ascitic fluid from various disease conditions. 
5) Cancer specific antigens immunorecogonised by protein microarray were identified by sequencing corresponding 
antigenic clones. 6-7) Novel putative antigens were validated by ELISA and their clinical correlation was determined.  
10.2 cDNA Library construction and characterization  
The cDNA phage library used in this study was constructed and extensively characterized as 
described in Di Niro et al [60]. The library was constructed using cell lines and tissue samples 
from three different source: colon carcinoma (HCC), fibroblasts (HF) cell lines (representing 
intestinal cell components) and isolated pancreatic human beta cell (HPI). mRNA from three 
different source (HCC, HF and HPI) was isolated and mildly fragmented by optimal heating to 
obtain calibrated fragment length ranging from 100 to 700 bp with an average of 350 bp prior to 
reverse transcription with an ideal concentration of random primers. The resulted single-stranded 
cDNA was then normalized individually with a corresponding mRNA. Later asymmetric adaptors 
with BssHII or NheI restriction site at 5’ or 3’ end, respectively was added. This step ensures a 
correct sense orientation of these cDNA fragments.  Finally, the cDNA library was cloned 
upstream of the beta lactamase gene of pPAO filtering vector and clones encoding ORFs were 
filtered out using ampicillin selection. Consequently, cDNA library of approximately 2x106 clones 
was generated. This ORF enriched library was endured to Cre-lox mediated recombination by 
replacing β-lactamase gene with phage coat protein gene, thus encoding  ORF as their fusion 
partner and used to perform selection.  The genetic composition of the selected library was 
characterized by 454 sequencing to assess both quality and diversity: more than 21,000 genes were 
found to be represented with an efficient normalization of gene abundance. 
Total Number of Sequences 1.5 million 
Average Length 245 
Genes More than 21,000 
 
Table 8: Gene abundance. cDNA fragments from selected phagemids were identified and ranked by 454 sequencing. 
The reads were mapped onto the human genome reference sequence using GMAP software and sequence and the 
corresponding mapped genes were identified.  
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10.3 Sample preparation  
Ascites were collected from 153 patients representing various disease conditions that includes: 
- Ascites from patients diagnosed with ovarian cancer (69),  
- Other cancers (34) and 
- Non-cancerous control ascitic fluid (50) from female patients with no known history of 
cancer (Table 9).  
Sets of Ascitic fluid  Classification  Application Used No: Used 
 
 
Ascitic Fluids 
(153 samples) 
 
-  Ovarian cancer (69)  
-  Other cancer (34) 
-  Non-Cancerous control (50) 
Western Blot 20 samples 
IFA  10 samples 
Cell lysate ELISA 74 samples 
Whole cell  ELISA 74 samples 
Phage display Selection  7 samples 
Protein Microarray 17 samples 
ELISA Validation All 153 samples 
Table 9: Summary of ascetic fluids used: A total of 153 ascitic fluids used were further classified into three groups 
based on the patients from they were collected; ovarian cancer, other cancer and non cancerous conditions. Numbers 
in brackets indicate the number of patients for each group. The number of ascites used for all different application are 
also indicated. 
 
In our preliminary experiments using ascitic fluid in its natural state, we observed a hindrance due 
to presence of abundant proteins such as human serum albumin. Hence, the IgG fractions of the 
ascitic fluids samples were affinity purified with Protein A. Figure 11A gel loaded with equal 
volume of unpurified ascites shows  presence of high concentration of HSA (66.5KDa) in 
comparison with immunoglobulins (50KDa heavy chain and 25KDa light chain). Affinity 
purification with protein A resin enabled to remove serum albumin (HSA), the major component 
and other components including cell debris (Fig 11B). Purified IgGs were quantified and check on 
a SDS-PAGE gel [Fig 11 A-B]. From the quantification, it can be seen (Fig 11 C) that various 
samples shows considerable variability in their concentration of IgG ranging from 8 to 1μg/μl with 
an average of 3μg/μl.  Quantified IgG were normalised to 1μg/μl (Fig 11 C-D) and were used for 
the proceeding experiments. 
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Figure 11: Affinity purification of  immunoglobulins: A) SDS-PAGE gel shows ascitic fluid prior to purification. B) 
Gel showing the immunoglobulins obtained after purification of ascites using protein A agarose. C) The graph shows 
the varying range of purified IgG concentration after purification. D) All IgG purified from ascites were normalized 
to a concentration 1µg/µl and were used for all proceeding experiments. group of samples of IgG. 
Ovarian cancer ascitic fluid represents stage I-VI collected from both platinum sensitive and 
resistant patients with grade ranging from G1-G3. Cancer other than ovarian cancer includes 
cancer of lung, liver, colon, fallopian tube, breast, gallbladder, pancreas, rectum, lymph nodes, 
lymphoma, various mesothelioma including peritoneal lining, adinocarcinoma of pulmonary, 
gastric and other organs. While, non-cancerous ascites collected from patients having conditions 
such as cirrhosis caused by various reasons, pulmonary fibrosis, cholestatic liver diseases, 
pneumonia, accumulation due to various transplantations, heteroplasia, inflammation etc. 
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10.4 Characterization of ascitic fluid based on autoantibody response 
To identify the presence of an anti self-antibody signature in the samples from  cancer patients and 
controls were analyzed by Western blotting and  ELISA (using extracts of tissue culture cells as 
source of antigens) as well as  by indirect immunofluorescence on whole cells. 
10.4.1 Western blot of ovarian cancer cell lysate 
The occurrence of antibodies targeting proteins in OVCAR-3 cell extract was investigated initially 
by Western blotting. An equal amount of OVCAR cell lysate was loaded into each well and later 
transferred to a nitrocellulose membrane. Recognition of the antigen was compared between 
twenty IgG purified and normalized (1µg/µl) cancerous ascites and controls. In figure 12 four 
representative nitrocellulose membrane strips incubated separately with purified ascites, two each 
from ovarian cancer (#3, #18) and noncancerous control (#1201, #1202).  The result (Fig 12) shows 
that cancer derived ascites recognized a higher number of antigen present in OVCAR3 cells 
compared to controls, verifies the presence of tumor specific antibodies targeting ovarian 
carcinoma cellular antigens.  Although, the ascites #3 and #18 collected from ovarian cancer, 
pattern of antigen recognized are very different from each other with few common bands in varying 
intensity.   Therefore, a more quantitative and reproducible methods was adopted to better 
understand the immunoreactivity of the full panel of purified ascites using a minimal volume as 
possible. 
 
 
Figure 12: Western blot of OVCAR3 cell lysate.  Each strip contains equal amount of OVCAR3 cell  lysate and were 
incubated separately with IgG purified ascites. Ascites #3 and #18 from ovarian cancer patient. #1201-#1202 are non 
cancerous controls. The immunoreactivity detected with anti human IgG AP conjugated secondary Ab. 
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10.4.2 Ovarian cancer whole cell ELISA 
Whole cell enzyme linked immunosorbent assay is convenient method that can accurately quantify 
both soluble as well as insoluble intracellular proteins/ tumor associated antigens in cultured 
adherent cells as well as a possible alternative to immunohistochemical characterization of tumors 
[144]. OVCAR-3 cells were grown and fixed on a 96-well plate. Targets of interest are detected 
by primary antibodies purified form ascitic fluid, which are in turn are quantified with α-human 
immunoglubulin labeled secondary antibody. The cell-ELISA experiments were performed in 
triplicate for each sample and the results were reproducible. For each experiment, the cut-off value 
was calculated as cumulative mean + 2 SD (standard deviation) of the absorbance from non-cancer 
control samples. As shown in figure 13, eighteen out of twenty-eight IgG samples from ovarian 
cancer gave a signal above the cut-off value, indicating that they do recognize targets present in 
OVCAR3 cells. While IgG samples from other cancer types were less reactive as only 6/18 were 
above the cut-off. Only 1 out of 28 non-cancerous samples was positive, others were shown to be 
below the cutoff value and indicating the absence of tumor specific antibody.   
 
Figure 13: Ovarian cancer whole cell ELISA: Fixed and permeabilized 80% confluent OVCAR cells were incubated 
with 1:100 dil of purified IgG from Ovarian cancer ascites, other cancers and non-cancerous controls. 1:2000 dil of 
detection antibody αhIgG-HRP was added.  Developed using TMB substrate and stopped with 1N H2SO4.  OD was 
measured at 450nm.  
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10.4.3 Ovarian Cancer Cell Lysate ELISA 
In addition to the whole cell ELISA, we also performed a total cell lysate ELISA with OVCAR-3 
cells to examine the prevalence of antibodies present in test and control sample targeted against 
soluble intracellular proteins/ TAA’s in OVCAR3 cells.  The cell extract was prepared under non-
denaturing conditions and the soluble fraction was quantified by BCA. The microtiter plate coated 
with the soluble fraction of OVCAR3 cell extract were challenged with 1: 50 diluted human IgG 
(1 μg/μl) from 28 ovarian cancer patient, 18 patients having other cancers and 28 non-cancerous 
control. Figure 14 shows the results from the cell lysate ELISA. We observed the presence of 
antibodies particularly in ovarian cancer sample (23/28) which recognizes TAA’s as compared to 
other cancer or non-cancerous control (0/18 and 3/28 respectively). It is evident that cell lysate 
ELISA detects more number of sample as positive as compared to whole cell ELISA. This may be 
due to the antibodies in ascitic fluid gets more access to find their target when cell lysate is used. 
Unlike whole cell ELISA, this assay contains only soluble antigen in the lysed fraction and thus 
detected none of the other cancer as positive.  
 
Figure 14: Ovarian Cancer Cell Lysate ELISA: .OVCAR3 cell lysate were prepared in a non-denaturing condition. 
Microtiter palate was O/N coated at 4o C with OVCAR3 cell lysate. Blocked with 2% BSA in PBST (0.05%).  
Incubated with 1: 50 diluted purified primary IgG for 1 hr 30min at 30o C. 1hr at 30o C with 1:5000 diluted secondary 
αhIgG-HRP was added to each well.  Added TMB substrate and stopped with 1N H2SO4. Read at 450nm. 
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Result from both these cell based ELISA tests provided a quantitative information, clearly 
differentiating ovarian cancer from non-cancer patients (P<0.0001 for both whole cell and cell 
lysate ELISA) and other cancerous conditions ((P=0.01), (P<0.0001) for whole cell and cell lysate 
ELISA respectively) and hence permitted to rank patients with elevated tumor specific antibody 
levels in ascitic fluids.  
10.4.4 Immunofluorescence Assay on OVCAR3 Cells (IFA) 
Further, antibody response was analyzed by immunofluorescence assay on OVCAR3 Cells. In 
order to observe various localization, staining of live ovarian cancer cells was performed to detect 
cell surface antigens. Simultaneously, the cells were fixed and permeabilized, thus permitting more 
access for ascite antibodies to find their intracellular target. Live OVCAR-3 cells were incubated 
with ascite antibodies for 2 hrs. To exclude the possibility that cellular uptake of antibodies, 
incubations were performed at 4°C which, only resulted in binding to the cell membrane since 
cellular uptake does not occur at this temperature. In figure 15, image A and B represents the cell 
surface localization of tumor specific antibody was detected with α-human immunoglubulin 
conjugated to Cy5 (in green). Nuclei were stained with Propidium iodide (in red). Live OVCAR-
3 cells when incubated with cancer ascite #44 (image A) shows a prominent signal of cell surface 
staining as similar to the positive control (image B). The mAb MOV18 (humanised α-Folate 
antibody) directed against the isoform  α of the folate receptors which are over expressed by 
endothelial ovarian cancer cell on their cell surface was used as positive control for this assay 
[145,146]. Other localization of target antigen was observed when the same cells were fixed and 
permeabilized. Image C shows nuclear localization (with cancerous ascites #18) while cytoplasmic 
(C) localization was clearly observed when incubated with control IgG #1385. Cells incubated 
with either acitic fluid from non-cancerous patient or healthy human IgG (image F) failed to 
produce any signal of binding.  
Taken together  the results suggest that the presence of tumor specific antibody targeting cancer  
proteins  and  help us to identify ascites which have high-titer fluorescent staining or strong signals 
to ovarian cancer cellular antigens and subsequently use them to isolate ORF clones by Phage 
Display. 
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Figure 15: Immunofluorescence assay on OVCAR3 Cells.  Cell Surface Staining:  (A, B) Image A represent cells 
incubated with cancerous ascite (#44). (B) Positive control humanised α-Folate antibody.  Fixed and Permeabilized 
cells (C,D,E and F) were separately incubated with either cancerous ascites (Image C and E: incubated with ascite #18 
and #1385 respectively) , (F) Cells incubated with non Cancerous ascite (1206) or Anti BCOR antibody (D). The 
intracellular localization of  tumor specific antibody was detected with α-human immunoglubulin conjugated to Cy5 
(in Green).  Nucleus were stained with Propedium iodide (in red). Image A-B shows the surface localization. Nuclear 
(C-D) and cytoplasmic (E) localization were clearly observed. Cells incubated with either acitic fluid from non-
cancerous patient or healthy human IgG failed to produce any signal of binding. 
 
10.5 Selection of ORF Phage Display Library  
The Phage Display technology approach was used to identify novel TAAs. A phage library of open 
reading frame (ORF) fragments created from mRNA derived from various tissues were used [60, 
147].  This library comprised of nearly all genes present in human genome. Characterization by 
massive sequencing of this library confirms that it represents more than 21,000 different genes or 
gene fragments.  
The following step are briefly summarized  for the selection of polypeptides from the cDNA 
libraries (Fig 16), with the purpose of isolating clones reactive to antibodies of interest, purified 
from ascitic fluid, from the background represented by all other phage clones.  
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1. Library amplification and phage particle production: The ORF filtered cDNA library was 
expressed and collected as a phage population. 
2. Enrichment by immunoprecipitation of phage particle with immobilized target: Purified ascitic 
antibodies were immobilized G-protein functionalized magnetic beads were then incubated 
with the population of phages resulting from the cDNA libraries. A negative selection or ‘pre-
clearing’ step was introduced before each round of selection. Phages were incubated with 
antibodies purified from healthy donors and unbound phages were collected and used for 
selections.  Later, beads functionalized with antibodies from ovarian cancer patients were 
incubated with pre-cleared phages.  
3. Washing steps: Extensive washes were performed to remove unbound phages. 
4. Elution and amplification of bound phages by infecting host bacteria: Bound phages were 
eluted with DH5αF’ bacterial culture and planted onto agar plates. 
 
 
 
 
Figure 16.  Schematic representation of the four steps followed for the selection of phages selection. 
Results 55 
 
 
 
ORF displaying phages were selected with ascitic fluid collected from patients diagnosed with 
ovarian cancer, which has already been characterized as most reactive based on the result obtained 
from the initial immunological assays (Table 10).  
Ascite ID Stage Grade Age at diagnosis Cells in ascites Histology Sensitivity to 
platinum 
44 I G2 51 Numerous Non Serous Sensitive 
49 II G3 61 Rare/some Serous Sensitive 
61 II G3 64 Rare/some Serous Sensitive 
3 III G3 60 Rare/some Serous Resistant 
18 IIIC G3 69 Absent Non Serous Resistant 
1385 IIIC G3 68 Numerous Serous Resistant 
51 IV G2 43 Numerous Non Serous Resistant 
Table 10: Purified ascites used for phage display selection. These ascites were chosen from the ranking list based on 
initial immunocharacterization for there reactivity towards antigen present in ovarian carcinoma cells.  
We performed seven independent screenings using the seven most reactive ascites. Two successive 
rounds of selection based on affinity selection permitted the enrichment and isolation of less 
abundant interacting proteins from a library with large diversity. Before each round, a “pre-
clearing step” was introduced by incubating phages with sera/immunoglobulins from healthy 
blood donors with an intention to eliminate the polyreactive clones. The stringency of washing 
steps were progressively increased between different cycles. In all cases, about 1011 phages were 
the input of the selections. Whereas, the output titre was variable, in the range of 105-106. The 
bound phages were eluted with DH5αF’ bacterial culture and planted onto agar plates. Output data 
of the three selection cycles are reported in Table 11: 
Ascite ID 1st IN 1st OUT 2nd IN 2nd OUT 
44 1011 2 x 106 1011 106 
49 1011 106 1011 2 x 105 
61 1011 3 x 105 1011 105 
3 1011 5 x 106 1011 106 
18 1011 106 1011 2 x 106 
1385 1011 106 1011 5 x 105 
51 1011 4 x 105 1011 106 
 
Table 11: Input and Output of phage populations for each selection round with different ascitic fluid. For each 
selection, patient ID (indicated as a number) Input (IN) and Output (OUT) phages are shown. 
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The first round of selection was performed with all the seven ascites at the same time. The input 
for this initial round was the NS library [60]. The second round was performed in similar manner 
for each single ascites individually but with the input as library obtained after the first round of 
selection. 
In order to evaluate the absence of any possible bias (i.e. short fragments) introduced throughout 
the selection process, the input and the output of each selection was screened and the variability 
of the fragments selected was determined.  
14 random clones from the input and output phages were checked by PCR by using specific 
primers for the phagemid vector. The length of the insert was determined by running of a 1% 
agarose gel. 
Figure 17 shows the variability of 28 random clones, the first 14 derived from the NS library 
represents the input for the first round of selection and the others 14 were the output of the first 
round of selection for the ascite #44. For all the input and output fragments analyzed the mean 
length was 350bp with a range between 150bp and 700bp.  No clear enrichment or specific 
fragments were shown, meaning that the process was not introducing bias for short fragments 
throughout the selections. 
 
Figure 17: Random clones checked for the input and the output of the selections. PCR products of 28 random clones 
loaded on agarose gel screened for variability. 
10.6 High-throughput protein production of the selected clones 
After two rounds of selections, the immunoscreened phages were sub cloned into an expression 
vector, modified pGEX Vector: pGEX 4T- 1 mut BssHII NheI (Fig 18). After subcloning, they 
were amplified in the host bacteria BL21 (DE3) RIPL cells for enhanced protein production. 95 
single clones from each of the 7 selections were randomly picked from agar plates and inoculated 
into 96 deep well plates in order to produce GST fusion protein.  This modified vector was 
constructed with  BssHII and NheI restriction sites and fusion tags, the N-terminal fusion with 
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GST, a highly soluble protein and C-terminal FLAG protein was introduced to improve the quality 
of protein by permitting better folding of the downstream polypeptide thereby avoiding inclusion 
bodies formation and to monitor the degradation. In addition, GST fusion proteins facilitate the 
purification by affinity separation (Fig 19).  
 
Figure 18: pGEX 4T- 1 mut BssHII NheI Vector Map 
 
Figure 19: Subcloning of the selected cDNA fragments from phagemid vector into modified pGEX vector. cDNA 
fragments were cloned into BssHII and NheI sites of pGEX vector; the library was plated in ampicillin to select ORF. 
95 single clones from each of the 7 selections (95 x 7) were randomly picked from agar plates and recombinant proteins 
were produced in a highthroughput format.   
The presence of the insert was confirmed by PCR analysis before they were cloned into a pGEX 
expression vector (Fig 20).  These immunoprecipitated ORF clones were expressed as GST-fusion 
proteins by transforming BL21 (DE3) RIPL cells with this expression vector.  
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Figure 20: PCR confirms the presence of insert. These PCR fragments were cloned into pGEX 4T-1 mut BssHII NheI. 
A bacterial expression system using E. coli in a 96 deep well plate allows high-throughput 
production and screening of recombinant proteins from the selected cDNA library. It is very 
convenient system to work with, as well as non-expensive and consequently yielding good quality 
purified protein in small amount for protein array screening. In this account, an automated mini-
fermenter (Fig 21) based on inflation of air developed in our laboratory was used for a better 
bacterial growth and improved protein production compared to the standard shaking or agitation 
method. This system consist of a compressor as a source of air which is connected to a circuit 
formed by a pressure gauge , a computer that regulates the entry of air through an electric valve 
and an incubator, maintained at a constant temperature in which 96 well plate can be placed. The 
air flow is directed to a plastic case, containing multiple layers of grid like gauges designed to 
equally distribute the air pressure through each of the 96 hollow stainless needle at the bottom of 
the plastic case. The plastic case can be connected to the 96 deep well plate with this needle dipped 
into the culture medium.  This allows inflation of air into each well of the 96 well plate in which 
the bacteria grow. All the condition such as the air pressure, inflation rate per minute, diameter of 
the needle etc. were previously been optimized.  
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Figure 21: Mini-fermenter: A) Schematic representation of the mini-fermenter, B) The grid inside the plastic casing. 
Subsequently, a high-throughput system developed by Studier in 2005 [148] and previously been 
optimized in our laboratory was adapted for the expression and purification of 700 random clones. 
Here an autoinduction medium for protein production in Lac promoter expression system was 
taken into account. This optimized medium allows bacterial growth without the activation of the 
genes coding for the recombinant proteins before the bacteria have reached the desired optical 
density.  Induction of Lac promoter of the bacteria causes the production of T7 polymerase thus 
leading to the transcription of cDNA fragment located downstream of the T7 promoter in pGEX 
vector and an enhanced protein production. This resulted in a synchronized growth and 
simultaneous induction of 700 different clones at the same time producing comparatively equal 
amount of proteins.  
A robust protocol for the multiplexed purification of recombinant proteins generated by our 
laboratory was used purify several hundred proteins in a 96 well format at considerable speed. 
Each single step of the procedure was previously been optimized to get an acceptable yield and 
quality of the purified proteins. The most important steps in this procedure are summarized in 
figure 22 and briefly explained. In order to avoid centrifugation step of the culture plate to have 
cell pellets, a choice was made to use a commercially available lysis buffer (FAST Break, 
Promega) that acts pretty well on the cells on culture. Later, the GST-fusion proteins were affinity 
purified with magnetic beads coated with reduced glutathione (GSH). Purification steps was 
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performed by means of magnetic devices. GSH-magnetic beads were used in that representing a 
good tool for the high-throughput processing: no need for centrifugation or filtration steps were 
required; volumes used were easily scaled in order to optimize yields with a reduced reagents 
consumption; by means of a magnetic plate and a 96-plexed manifold, washing steps and elution 
were performed in a short time. 
 
Figure 22:  Workflow of the high-throughput protein production and purification protocol. 
To ensure a proper production, a few random selected proteins were denatured and loaded on a gel 
for SDS-PAGE. The coomassie stained gel shown in figure 23, a final concentration in the eluted 
sample ranging from 0.1 up to 1 μg/μl. The quality of proteins produced was generally good: an 
acceptable level of a slight contamination of known co-purified high molecular weight bacterial 
proteins was observed. Western blot (with anti-GST and anti-FLAG primary antibody) was carried 
out to check whether the expressed proteins were full length fusion protein. A variable degree of 
degradation was moreover observed, but full-length proteins were always present in the sample 
(data not shown). 
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Figure 23: Coomassie staining of GST-fusion proteins produced by high-throughput approach. 2μl of each protein 
sample were loaded. Dilutions of a BSA sample (amount: 0.5 and 1μg) were introduced as calibrator. 
The procedure led to the production of 96 recombinant proteins/day, with the quality and the 
amounts required for the production of a high density protein microarray to be screened with 
purified ascites. 
10.7 Immunoscreening of the selected antigen by protein microarray 
ORF displaying phages after successive and stringent rounds of selection were initially validated 
for their immune recognition by protein microarray. Protein microarrays are very reliable and 
extensively been used for the identifying novel antigens in cancer [68,110,125,126,135,137]. 
Besides their ease of use to analyze a large set of biomolecules, they require less amount of sample 
and reagent, making them a choice of interest.  96 bacterial clones from each of the 7 screenings 
were randomly selected and proteins were expressed and purified in a 96 deep-well (1.2 ml liquid 
culture) format, yielding approximately 700 independent GST fusion proteins. Purified proteins 
were spotted onto nitrocellulose slides along with controls and calibrator IgGs and screened for 
their immunoreactivity. Protein microarray is a high throughput approach, which simultaneously 
can analyze all these selected proteins. To ensure the proper printing of full-length proteins on 
slides, an array was incubated with anti-GST (Fig 24A). Later, each array were challenged 
individually with 17 different ascitic fluid collected from patients representing different disease 
conditions: 
- 13 ascitic fluid out of 17 were collected from patients suffering ovarian cancer,  
- 2 from cancer patients other than ovarian and 
- 2 ascitic fluid collected from non-cancerous conditions.  
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The reactivity was revealed with anti-human IgG antibody as shown in figure 24 where each 
antigenic protein are printed as duplicate spots and normalized for signal intensity by using the 
IgG calibration curve. A cut-off value was calculated using the signal intensity produced when 
incubated with non-cancerous ascitic fluid. Here identical arrays show difference in 
immunorecognition when incubated with ovarian cancer ascites (Fig 24 B) in comparison with 
non-cancerous ascites (Fig 24 C). Seventy three highly positive antigens found to have a threshold 
values for determining reactive clones were arbitrary established at Signal to Noise (S/N) ratio 
greater than 3. These identified antigens were specifically reactive towards ovarian cancer ascites 
in contrast to non-cancerous ascites for their immunoreactivity.  
 
Figure 24: Immuno-screening by protein microarray:  Fluorescent signal from arrayed antigen.  A) Array challenged 
with α-GST as positive control for expression of full length recombinant proteins. Image B and C:   Fluorescent signal 
from array screened with cancerous ascetic fluid and noncancerous control respectively . All the printed proteins were 
challenged against 1:50 dilution of 17 different Ascitic fluid collected from patients representing different disease 
conditions including control. 
10.8 Identification of novel putative tumour-associated antigens (TAA) by sequencing  
The plasmids encoding the genes of these 73 identified proteins were extracted and the cDNA 
were amplified by PCR and sequenced with the Sanger method. All the 73 immunoreactive clones 
were PCR amplified with pGEX primers and were run on a 1% agarose gel (Fig 25). 
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Figure 25: PCR of immunereactive clones amplified with pGEX primers. Amplified fragments have shown to have a 
size ranging 150-800bp  
It was observed from the gel that the size of the amplified fragments vary between 150-800bp, 
which complies with the initial dimension of the cDNA fragments (this size range will be correctly 
displayed by the phage on the caspid) used for the construction of phage display library. Fragments 
representing each size were further purified and subjected to sequencing.  
Gene fragment display suffers from the problem that only one clone in 18 is functional, due to the 
orientation of the fragment and the reading frame in which they are translated.  It has been noticed 
from the result that majority of the fragments are composed of 3N bases suggesting the cDNA 
library was well ORF filtered. From the sequencing result, we matched our sequences to the 
genetic sequences available in blast database and later translated to identify the protein expressed 
by this cDNA. Hence, decided to evaluate only the ‘genic ORFs’ ie those cloned fragment with 
3N bases,+1 reading frame of translation carrying both the BsshII and Nhe I restriction sites. The 
mimotopes or the nongenic ORFs were removed from the list. Following the sequencing, we 
observed that many clones constituted ORFs encoding different fragments of the same protein. 
Among the identified proteins, we decided to initially validate those which were positive with all 
the ovarian cancer ascitic fluids analyzed (Table 12). 
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Name HUGO Name Subcellular 
Location 
Function Length 
(bp) 
Homo sapiens cAMP responsive element 
binding protein 3  
CREB3 Nucleus,  
Cytoplasm 
Transcription factor 303 
Homo sapiens mitochondrial ribosomal protein 
L46  
MRPL46 Mitochondrion Hydrolase  activity  231 
Homo sapiens exosome component 10  EXOSC10 Cytoplasm, 
 Nucleus 
rRNA Processing 204 
Homo sapiens BCL6 corepressor  BCOR Nucleus Transcriptional 
corepressor 
228 
Homo sapiens huntingtin interacting protein 1 
related  
HIP1R Cytoplasm, 
 Perinuclear 
region 
Receptor-mediated 
endocytosis 
396 
Homo sapiens high mobility group nucleosomal 
binding domain 2  
HMGN2 Nucleus, 
 Cytoplasm 
Chromatin organization,  
Regulation of 
transcription 
261 
Homo sapiens olfactomedin 4  OLFM4 Secreted,  
 
Mitochondrion 
Cell adhesion 129 
Homo sapiens KIAA1755  KIAA1755   156 
 
Table 12: Identified novel putative tumor associated antigens selected for validation. The table summarizes the 
cellular localization and function of each of the identified genic antigens. 
  
10.9 Large Scale Production of Novel Putative Antigens 
The antigens screened by protein array and identified by sequencing were produced in higher 
quantities in order to be validated by ELISA. The recombinant proteins were purified by affinity 
chromatography, using the GST- tag. All the expressed and purified proteins were quantified and 
were analysed by Coomassie staining (Fig 26 A) and Western blot with both αFLAG (Fig 26 B) 
and αGST (Fig 26 C) primary antibody, to ensure the full-length protein production and to monitor 
the level of degradation. 
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Figure 26: Expression and Purification of Antigens: A) Coomassie staining, molecular weight and western blot of all 
predicted antigens with B) α-FLAG antibody, C) α-GST antibody and the respective membrane stained with ponceau. 
D) Eight top antigens with their corresponding molecular weight in kilo Dalton. 
10.10 Validation of Putative Antigenic Protein by Indirect ELISA 
ELISA was performed to determine whether the antibodies present in the ascitic fluid from the 
ovarian cancer patients were specifically recognized by the selected peptides derived from the 
screenings. This techniques offer a higher level of sensitivity to measured autoantibodies even at 
a very low concentration. Each well of ELISA plate was coated with 1μg recombinant protein in 
100 μl PBS. Each antigen was validated separately by ELISA against a set of 153 protein A 
purified ascites from various disease conditions (Table 9). First tested with a set of ascites which 
includes 69 ovarian cancer, 34 other cancer and 50 noncancerous cancerous controls (Fig 27). The 
sixty-nine ovarian cancer ascitic fluid includes stage I-VI collected from both platinum sensitive 
and resistant patients with grade ranging from G1-G3. Out of all antigens tested, eight showed a 
statistically significant difference in immunoreactivity between ovarian cancer and non-cancerous 
control ascites as reported in figure 27 and summarized in table 12. The prevalence of 
autoantibodies in ovarian cancer patient is described by the P-value, calculated using two tailed 
unpaired t-test: antigens with P-value<0.05 are considered significant. These eight identified as 
novel putative TAAs  includes A) CREB3 (Cyclic AMP-responsive element-binding protein 3) B) 
MRPL46 (Mitochondrial ribosomal protein L46) C) BCOR (BCL-6 corepressor) D) HMGN2 
Results 66 
 
 
 
(High mobility group nucleosomal binding domain 2) E) HIP1R (Huntingtin interacting protein 1 
related) F) EXOSC10 (Exosome component 10) G) OLFM4 (olfactomedin 4) and H) KIAA1755. 
The full-length production and purification of these antigens are shown in figure 26.  
 
 
O
va
ri
an
 C
an
ce
r
O
th
er
 c
an
ce
r
N
on
-c
an
ce
r
0.0
0.5
1.0
1.5
2.0
2.5
P<0.0001
P=0.0043
           CREB3
60/69                         20/34                        1/50
N
o
rm
a
li
z
e
d
 O
D
 a
t 
4
5
0
n
m
MRPL46
O
va
ri
an
 C
an
ce
r
O
th
er
 c
an
ce
r
N
on
-c
an
ce
r
0.0
0.5
1.0
1.5
2.0
2.5
P<0.0001
P=0.0102
51/69                       18/34                         2/50
N
o
rm
a
li
z
e
d
 O
D
 a
t 
4
5
0
n
m
EXOSC10
O
va
ri
an
 C
an
ce
r
O
th
er
 c
an
ce
r
N
on
-c
an
ce
r
0.0
0.5
1.0
1.5
2.0
P<0.0001
P=0.0784
39/69                       12/34                         1/50
N
o
rm
a
li
z
e
d
 O
D
 a
t 
4
5
0
n
m
BCOR
O
va
ri
an
 C
an
ce
r
O
th
er
 c
an
ce
r
N
on
-c
an
ce
r
0.0
0.5
1.0
1.5
2.0
2.5
P<0.0001
P=0.0420
50/69                       22/34                           0/50
N
o
rm
a
li
z
e
d
 O
D
 a
t 
4
5
0
n
m
Results 67 
 
 
 
 
Figure 27: Validation of antigenic protein by ELISA. Each antigen was challenged with 1: 50 dilution of a total 153 
IgG purified ascites (1µg/µl) which further is divided into 3 different groups i) Ovarian cancer (69) ii) Other cancer 
(34) iii) Non-cancerous control (50). Cut-off value was calculated separately for each antigen as mean + 2(standard 
deviation) of the OD from all non-cancerous control wells. Significance for ELISA data obtained for each antigen are 
reported. The prevalence of autoantibodies in ovarian cancer patient is described by the P-value, calculated using two-
tailed unpaired t-test: antigens with P-value<0.05 are considered significant. 
Concerning the reactivity, each of the eight antigens have shown to produce a varying range of 
immunorecognition with different group of ascites. CREB3, MRPL46, BCOR and EXOSC10 were 
proved to be most sensitive and can detect 60/69, 51/69, 50/69 and 39/69 ascites derived from 
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ovarian cancer patients as positive. Were as, KIAA1755 detected 26 out of 69 as positive. 18/69 
and 17/69 were predicted to be above the cutoff by HIP1R and OLFM4 respectively. HMGN2 was 
the least sensitive among the panel and predicted 13/69 to be positive. However, among all eight 
antigens, only four antigens namely CRB3, MRPL46, BCOR and OLFM2 were capable to 
differentiate ovarian cancer from patients suffering other cancer with a P-value<0.05.  The 
sensitivity and specificity of each antigen in detecting ovarian cancer are summarized in table 13. 
 
Name  Sensitivity  Specificity  
CREB 3 86.95% 98% 
MRPL46 73.91 96% 
EXOSC10 56.52% 98% 
BCOR 72.46% 100% 
HIP1R 26% 98% 
HMGN2 18.84% 94% 
OLFM2 24.63% 98% 
KIA1755 37.68% 98% 
 
Table 13: Sensitivity and specificity of detection. Sensitivity and specificity of each antigen in detecting ovarian 
cancer. 
 
Many previous studies on the use of a panel of markers have reportedly shown that combinations 
of multiple marker improve sensitivity and specificity for early-stage disease detection [24, 32-
34,36].  
10.11 Analysis for the prognostic potential of the novel antigens and their clinical correlation 
A significant association of autoantibody responses with better clinical outcome was found by 
comparing differences between curves with the log-rank method. Subsequently, clinical data of 
the corresponding patients were analyzed after the experimental phase of this study was completed. 
Patients with at least 18 months follow up details were used for the overall survival analysis. Figure 
28 shows Kaplan–Meier analyses of overall survival of ovarian cancer patients according to the 
presence of antibody response to these three identified antigens.  A log-rank method was used to 
evaluate their significance. Which resulted in a significant difference in survival time between 
patients producing surplus protecting antibody and non-producing patients against CREB3 (log 
rank p value = 0.05), MRPL46 (log rank p value = 0.006) or EXOSC10 (log rank p value = 0.05). 
Our data clearly implies that patients who overexpress any of the three antigen or produce high 
titer of antibody against CREB3, MRPL46 or EXOSC10 have a prolonged overall survival.  None 
of the other identified antigens showed any significant clinical correlation with the disease. 
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Figure 28: Antigenic markers with potential prognostic value. Kaplan-Meier analyses of overall survival of ovarian 
cancer patients according to the presence (positive) or absence (negative) of antibody response to CREB3, MRPL46 
and EXOSC10. Patients showing immune response to these antigens (pos) are represented as red line. Whereas 
patients who do not produce immune response (neg) are indicated as green.  A prolonged overall survival (in months) 
of the antigen positive patients was the outcome of this analysis as compared to antigen negative group of patients. 
10.12 Verification of Cell Surface Targets by Cell Surface ELISA on Live OVCAR-3 Cell 
Line 
Cell surface antigens represent only 1% of the total cellular protein (Fig 29) [149-151]. The 
presence of tumor specific antibody targeting surface antigens present on ovarian carcinoma cell 
line already been demonstrated by our immunofluorescence assay performed on live ovarian 
cancer cells (Fig 15).   
 
 
Figure 29: The ratio of surface targets which are accessible for humoral and cytotoxic immunity and remaining 
intracellular content [10].   
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Subsequently, a cell surface ELISA was performed on live OVCAR-3 cells to determine the 
presence and to quantify the amount of immunoreactive antibody present in ascitic fluid directed 
against cell surface tumor antigen. 80% confluent live OVCAR-3 cells were incubated with 1:50 
dilution of primary antibody (affinity-purified antibodies from ovarian, other cancer and non-
cancerous control). Later detection antibody was added to determine the presence of cell surface 
antigen. This assay was performed as triplicate and the average value of 3 wells were considered 
to be the OD of individual sample. The cut-off value was calculated as ‘sum of (cumulative mean 
+ twice the standard deviation) of the absorbance from non-cancerous control wells. 
 
 
Figure 30: Ovarian Cancer Cell Surface ELISA. Scatter plot representing cell surface ELISA performed on live 
OVCAR-3 cells. Each spot represent a mean OD value obtained from a triplicate wells. The cut-off value was 
calculated as ‘sum of (cumulative mean + twice the standard deviation) of the absorbance from non-cancerous control 
wells. 
Figure 30 shows the cell surface result for set of 147 ascitic fluid. 34.78% (24/69) of ascitic fluid 
from patients with ovarian cancer are shown have significantly higher signal for the presence of 
specific antibodies against cell surface tumor antigen as compared to 4/28 ascitic fluid from other 
cancer patients. Except 1 out of 50, none of the noncancerous controls (49/50) were unable to 
produce any signal, leaving them below the cut off. Cell surface ELISA facilitated to determine 
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the amount of immunorective antibody present in ascitic fluid directed against cell surface tumor 
antigen. In addition, this assay provides a highly specific in differentiating ovarian cancer patients 
from non-cancerous patients as well as patients having cancer other than ovarian with P-
value<0.0001 for both the cases.   
10.13 Role of Cell Surface Antigen Interacting Antibodies in Tumor Regulation by 
Complement Dependent Cytotoxicity (CDC)  
Our data confirm the presence of tumor specific antibodies in ovarian cancer ascites targeting 
surface antigen. To understand if these tumor specific antibodies when interact with cell surface 
antigen are capable to activate complement pathway and regulate tumor grown by complement 
dependent cytotoxicity. Ascitic fluids have previously been characterized by L Bjørge et al and are 
known to contain all the components required for compliment activation [48]. Additionally, based 
on the interesting findings from two independent studies demonstrating that the two chimeric 
mAbs cMOV18 and cMOV19 against α isoform of the folate receptor (FR) which recognizes two 
different epitopes  that are highly expressed on EOC cell surface are known to cause antibody-
dependent cell cytotoxicity (ADCC) and Complement dependent killing of various EOC cell lines 
including OVCAR-3 [51, 148]. These finding prompted us to investigate the presence of specific 
ascitic antibody collected from ovarian cancer patients and evaluate their ability to activate the 
complement system.  
To this extent, confluent OVCAR cells were incubated individually with ascitic antibody or 
mixture of cMOV18 and cMOV19 or no antibody control (diluted in DPBS supplemented with 
Ca2+/Mg2+). Further NHS containing complement factors were added to the cells to activate 
complement pathway which resulted in formation of membrane attack complex (MAC) on their 
cell membrane and lead to complement dependent cytotoxicity (CDC).  The residual viable cells 
as well as number of cells killed was estimated by the MTT assay (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide assay). The resulting purple solution is spectrophotometrically 
measured at 570nm and can be directly related to the number of viable (living) cells. The 
absorbance was measured at 570nm. Considering the cells with only NHS (‘no antibody’) as 100% 
living cells, the percentage of dead cells was calculated as:  % of dead cells = 100 – [100 x (average 
of cells +Abs)/ (Average of cells +NHS)]. As expected, a 25-30% of killing of OVCAR3 cells was 
attained by the mixture of cMOV18 and cMOV19 via complement activation was entirely in 
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agreement with Paolo Macor et. al [51]. Normalization of this assay was made by considering the 
percentage of killing obtained with the mixture of cMOV18/19 as 100% and any killing above 
10% caused by CDC were considered to be over the cutoff value. 
Figure 31: A) Complement dependent Cytotoxicity Assay of ascites from ovarian cancer and non-cancer patients B) 
comparative analysis of CDC assay versus cell surface ELISA of all ovarian cancer ascites 
As in figure 31A, 32 out of 68 ascitic fluid from ovarian cancer patients shown to have presence 
of tumor specific antibody which are capable to activate C system leading to the killing. None of 
non-cancerous sample IgG were able to cause killing, indicating the absence or presence of these 
specific antibody in very low concentration. Later, a comparative analysis was made between CDC 
assays and cell surface ELISA to understand their correlation.  Scatter plot (Fig 31 B) shows 75% 
of cell surface ELISA positive ascites are capable of mediating complement dependent killing of 
the ovarian carcinoma cell line. 
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Chapter 3 
11. Discussion  
11.1 Background  
Ovarian cancer is the seventh most common cancer among women and is the leading cause of 
death from gynecological cancers in women worldwide, accounting for more than 151,000 deaths. 
This is due to the lack of reliable and effective early detection methods, since majority of early-
stage of these cancers are asymptomatic and are detected at later stages, after they have invaded 
the surrounding tissues. Up to 90% of stage I ovarian cancer patients can be cured by currently 
available therapy. However, Only 25% of ovarian cancers are diagnosed in the early stage (Stage 
I) while they are confined to the ovaries. Ovarian cancer is characterized with the accumulation of 
ascitic fluid in the peritoneal cavity. These body fluids are excellent reservoir to study various 
biological aspects of the underlying tumor and equally important for the discovery of prognostic 
and predictive biomarkers. Because ascitic fluid persist in closer or direct contact with the tumor 
site and may contains many cells of tumor origin in addition to tumor secrete proteins, antibodies 
against these secreted or leaked proteins or peptides from tumorous tissue, soluble growth factors 
that have been associated with invasion and metastasis.  
To my knowledge, the study presented in this thesis represents the first systematic analysis to 
profile ovarian cancer antibody repertoire in ascitic fluid using a high-throughput proteomic based 
methodology.  The proteome of this heterogeneous, genomically unstable and highly lethal disease 
in women represents a complex molecular system: the major goal of present-day proteomics is to 
analyze proteins in their interactions with each other in a complex networks, which constantly 
changing over time and under different stimuli. Thus, requires methodologies allowing sensitive 
and simultaneous analysis of a large number of components.  The first challenge to overcome was 
the necessity of a high sensitive tool to detect these low abundant molecular targets or tumor 
proteins with an increased specificity. Secondly, the proteomic tool should have high multiplexed 
capability, to allow the analysis of the huge number of molecules underlying biological processes.  
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In this work, the immune system has been used as a model of complex biological systems, where 
the analysis of its complexity and interactions could give new important insights into the biology 
of the system, insights that were not possible if studying single components. In a same vein, 
significant practical applications could be found, for example in the development of novel, highly 
sensitive diagnostic and prognostic tools. 
Through the advent of the SEREX technology (serological identification of antigens by 
recombinant expression cloning procedure), the direct identification of immunogenic proteins by 
means of antibodies/autoantibodies present in body fluids derived from cancer patients was proven 
[189-192]. SEREX allowed the detection of novel antigens that could became potential candidates 
for diagnostic/prognostic tools, or probes for vaccination. Although extremely effective in 
identifying antigenic proteins, SEREX approach is a labour intensive procedure and requires a 
reduction in the panel of candidate antigens to be analyzed.  
With regard to characterize ovarian cancer ascitic fluids, we employed a technological platform 
that combines a selection of a phage display cDNA library followed by protein microarray. This 
innovative approach could help the simultaneous screening of a huge number of proteins, in order 
to identify novel autoantigens/tumor associated antigens involved in the disease; secondly, a 
molecular dissection of the immune response involved in such disease. Thus, to produce large 
datasets in a sensitive and reproducible manner, with reduced demand for time and reagents. 
Identified targets were validated and evaluated for their clinical correlation with the disease as well 
as prognostic potential to predict the patient survival outcome were examined. 
11.2 Immunoproteomic approach in the identification of TAAs 
Currently there are no efficient screening and detection methods available for ovarian cancer; thus 
still remains a challenge for the cancer researchers. By early detection, a tremendous decrease in 
mortality can be achieved. Keeping this as our fundamental objective, we have identified a set of 
TAAs with very high prognostic potential for ovarian cancer. 
Our strategy initially characterized ascitic fluids from various disease condition (ovarian cancer/ 
other cancer and non-cancerous sample) for their antibody response targeted against soluble, 
insoluble intracellular proteins present in OVCAR cells using various immunological assay which 
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includes western blot, whole cell ELISA, cell lysate ELISA on OVCAR cell line. This screening 
was done in order to identify the most reactive sample that could be used for phage display 
selection to screen out those interacting peptide displayed phages. Western blot analysis of 
OVCAR cell extract has proven to show the occurrence of cancer specific antibodies. The 
prevalence of antibodies present in cancerous and non cancerous sample targeted against soluble/ 
insoluble intracellular proteins in their non denatured form present in OVCAR cells were examined 
by whole cell ELISA and was confirmed by cell lysate ELISA on OVCAR3 cells. This data 
indicates that the ascitic fluid from ovarian cancer patients contains tumor specific antibodies 
which are absent in non-cancerous samples.  
Our immunofluorescence assay illustrates the presence of tumor specific surface antigen on live 
ovarian cancer cell line. The cell surface staining performed at a low temperature with same set of 
antibodies on live OVCAR3 cells. The result we obtained implies the presence of IgG determinants 
on cell surface such as surface antigens or receptors. Antibodies binding to these specific receptor 
gets internalised by endocytosis or pinocytocis [196,197]. Another possibility could be some of 
the intracellular antigens or proteolytic fragments of intracellular target might get externalised and 
displayed on the surface of cancer cells by unconventional secretion [152], enabling the antibodies 
to bind and trigger immune responses. The indirect immunofluorescence double staining 
performed on fixed and permeabilized OVCAR3 cells when incubated with cancerous ascites 
shows nuclear and cytoplasmic localization. As a control, cells incubated with either ascitic fluid 
form non-cancerous patient or healthy human IgG did not produce any signal.  
These results provide the first verification of tumor specific anti-self antibody signature present in 
ascitic fluid from ovarian cancer patients. The immunoreactivity of these antibody repertoires to 
same target antigen varies considerably in patients having ovarian cancer. Patients with cancer 
other than ovarian or having a non-cancerous condition lacked these antibodies targeting ovarian 
cancer cellular antigen. With these immuno-techniques, we identified and ranked patients 
according to elevated tumor specific antibody levels in their ascitic fluids having a high 
immunoreactivity to cellular antigen and subsequently use the purified antibodies to isolate ORF 
clones by Phage Display. The precise mechanism by which these antibodies produced against 
intracellular antigens have to be further investigated 
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Phage display expression libraries provide a simple and efficient approach for the identification of 
novel antigens, by allowing the screening of cDNA libraries created from appropriate tissues 
directly with antibodies contained in ascitic fluid from ovarian cancer patients. The cDNA phage 
library used in this study was constructed and extensively characterized as described in Di Niro et 
al [60]. Various important strategies were incorporated while the construction of this library. The 
concept of cDNA filtering by applying the pPAO display system developed by our laboratory was 
successfully introduced. DNA fragments were cloned upstream of the beta lactamase gene in this 
vector and clones produced were selected for ampicillin resistance. This resulted in elimination of 
out-of-frame DNA sequences in an effective way to reduce the amount of molecular diversity to 
be assessed in subsequent steps, while simultaneously enriching open reading frames (ORFs) 
corresponding to real genes with biological significance and desired functions.  This ORF enriched 
library was then fused with phage coat protein gene by Cre-lox mediated recombination, thus 
encoding ORF as their fusion partner and used to perform selection. A deep characterization of the 
non selected (NS) library by massive sequencing approach has revealed efficient normalization of 
gene abundance with the presence of good diversity of cDNA [60,141]. More than 21,000 genes 
were identified to be present in this library. In addition, that 90 % of the clones were determined 
to be open reading frame (ORFs) sequences, which are correctly expressed as a fusion partner on 
the phage surface.  These remarkable features of our library offers a rational advantage to be 
utilized for the selection of novel proteins potentially involved in the autoantibody response of 
patients suffering from ovarian cancer.  
Two rounds of selection were performed with magnetic beads functionalized with antibodies 
purified from ovarian cancer ascites which were found to be the most immunoreactive by initial 
immuno characterization. Thus, to screen out those peptide displayed phages which are recognized 
by immobilized antibodies present in the ascitic fluid from ovarian cancer patients but absent in 
healthy controls. The advantage of using phage display is that the selection of binding polypeptides 
leads at the same time to the isolation of the corresponding gene, allowing its manipulation and 
engineering and all downstream applications described in this work.  
A large set of clones selected by successive rounds of ORF phage display screening were expressed 
as GST-fusion proteins. Unlike the conventional immuno assay techniques, protein microarrays 
represent a novel approach for large-scale characterization of antibodies directed against these 
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large set of target simultaneously from a single experiment maintaining the same specificity and 
sensitivity with respect to standard immunoassay. Besides their ease of use to analyze a large set 
of biomolecules, they require less amount of sample and reagent, making them a choice of interest.   
In this work, we have demonstrated the applicability of this method for the multiplexed 
characterization of complex antibody responses. This approach was strongly enhanced by the 
combination of high-throughput production and purification of proteins in 96 well plate format. 
Approximately 700 different purified GST fusion proteins along with controls and calibrator IgGs 
were spotted onto nitrocellulose slides with the aid of a robotic system. These arrays of large set 
of proteins were immunoscreened by independent sets of cancer and control antibodies in 
microliter volumes; immunoreactivity was detected as fluorescent signal. The result (Fig 24 B-C) 
we obtained clearly indicates the specificity of this assay to distinguish potential antigens for their 
immunorecognition from identical arrays when incubated with ovarian cancer ascites (Fig 24 B) 
in comparison with non cancerous ascites (Fig 24 c). The quantitative data about the antibody 
reactivity of many ascitic fluids to a high number of proteins provided by this sensitive assay 
enabled us to isolate seventy-three highly reactive antigenic clones. This signifies microarray as a 
highly promising tool for the high throughput in profiling complex antibody responses. Moreover, 
combining protein microarray screening as concluding steps of phage selection permitted a drastic 
reduction in the large collection of protein derived from phage expression systems and to focus on 
few numbers of potentially important antigens. 
On characterizing these antigenic clones by Sanger sequencing, the most of the fragments selected 
represent genic ORFs, while a few clones represent alternative reading frames. Some of these non-
genic ORF encodes for polypeptide (known as mimotopes) even though having corresponding 
gene fragment in their incorrect reading frame. The mimotopes mimicking the structure of an 
antigenic epitope (both linear as well as conformational epitopes) are capable to elicit immune 
response as similar to antibody response caused by the conformational epitopes of real antigens 
and were recognized by the ascite antibodies [198,199]. Mimotopes or the nongenic ORFs were 
excluded from the validation list. While, based on the specific reactivity measured for each protein, 
eight most reactive antigens were identified to produce a strong significantly different immune 
response signal between all the ovarian cancer and control ascitic fluids screened by protein array 
and identified as genic ORFs by sequencing, were produced in higher quantities in order to be 
validated by ELISA.  
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11.3 Antigens Identified As Most Immunoreactive  
As expected, some of the isolated proteins found were associated previously with cancer and in 
various cancer related pathologies other than ovarian cancer although not necessarily as tumor 
antigens, thus confirming the efficacy of the approach and suggesting these antigens shares 
common pathways in various disease conditions.  
cAMP responsive element binding protein 3 (CREB3) gene spans 4669 bps of chromosome 9 at 
9p13.3 encodes for 395AA and exists 3 isoform. cAMP responsive element binding protein in 3 
(CREB3) is a transcription factor belonging to leucine zipper family of DNA binding proteins. 
CREB3 subfamily proteins are anchored to the ER membrane in an inactive form. Only upon 
stimulation, the CREB3 subfamily proteins are translocated by COPII vesicles from the ER to the 
Golgi apparatus where they will  proteolytically cleaved there by site 1 protease (S1P) and S2P 
sequentially to release the N-terminal fragment, which translocates into the nucleus  and might 
work as homodimers or heterodimers to activate the transcription of genes. [153].This transcription 
factors activated upon intramembrane proteolysis (RIP), binds the cAMP via a conserved gene 
promoter element CRE (cAMP response element), which has the sequence 5'-TGACGTCA-3' and 
regulates cell proliferation. Nuclear form of CREB3/Luman specifically binds the UPRE 
consensus sequence and activates transcription [154]. A previous study has demonstrated that 
HDAC3 selectively represses CREB3-mediated transcriptional activation and chemotactic 
signalling in human metastatic breast cancer cells [155]. CREB3 was known to be a binding partner 
of hepatitis C virus core protein. This interaction with the viral oncoprotein might interfere with a 
tumor suppressive function of CREB3 to promote cellular transformation in hepatocellular 
carcinoma [156]. Dendritic cells (DCs) are antigen-presenting cells (APC) of the immune system. 
Recently CREB3/Luman was identified to interact with as a DC-STAMP (Dendritic Cell Specific 
TrAnsMembrane Protein (DC-STAMP). Same group also demonstrated that CREB3/ Luman 
coimmunoprecipitated OS9, DC-STAMP-interacting protein. Suggesting LUMAN and OS9 are 
part of the same complex and interact with each other at the cytosolic site of the ER. Thus leading 
to a new proposed Model of DC-STAMP/LUMAN/OS-9 pathway in which DC-
STAMP/LUMAN/OS9 complex resides in the ER in immature DC and upon DC maturation, DC-
STAMP/LUMAN complex translocates to the Golgi, where LUMAN is subsequently cleaved and 
its amino-terminal region is liberated, which then relocates to the nucleus. OS9 does not alter their 
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localization [157]. The CREB3 epitope resulted from library screening fits in activated nuclear 
region as well as they overlap with a part of minimal region of CREB3/LUMAN needed for DC-
STAMP interaction.  
The fragment which was pulled down by phage display selection fit within the HRDC domain of 
human exosome component 10 (EXOSC10). EXOSC10 also known as Polymyositis/scleroderma 
autoantigen 2or PM/Scl-100 was identified as 100–110 kDa protein reactive with PM/Scl 
autoantibodies [158-160] with a high specificity [161]. Approximately 5–8% of the sera from 
myositis patients, 3% of those from scleroderma patients, and 24% of those from patients with 
PM/Scl overlap syndrome contain the anti-PM/Scl autoantibody. The autoantibodies that 
characterize this specificity are predominantly directed against the PM/Scl-100 antigen. 
Immunolocalization studies showed that the PM/Scl autoantigens are present in the nucleoplasm 
and, at higher concentrations, in the nucleolus. The nucleolus is the site of ribosome synthesis, 
which involves the transcription and nucleolytic processing of precursor rRNAs, the nucleotide 
modification of rRNAs, and the assembly of mature rRNAs with approximately 80 ribosomal 
proteins into small and large ribosomal subunits. In yeast (Saccharomyces cerevisiae), 11 proteins, 
10 of which are known or predicted to have 3’-5’ exoribonuclease activity. Yeast exosome 
components, namely Rrp6p are homologous to the PM/Scl-100 autoantigens. Functional studies 
suggest their presence in the nuclear and cytoplasmic compartments. Exosome is involved in the 
processing and degradation of several RNA species. The cytoplasmic exosome subfraction is 
probably involved in the degradation of mature cytoplasmic mRNAs.  The human counterpart of 
the yeast exosome was shown to exhibit 3’-5’ exoribonuclease activity [162,163]. The isolated 
GST fusion protein MRPL46 is a short N terminal fragment of mitochondrial ribosomal proteins 
L46. Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and help in 
protein synthesis within the mitochondrion. Mitochondrial ribosomes (mitoribosomes) consist of 
a small 28S subunit and a large 39S subunit. This gene encodes a 39S subunit protein [164]. Their 
expression is enriched in testis. 
BCOR was originally identified as a novel corepressor of BCL-6 repressor and selectively 
potentiate BCL-6 repression. BCOR gene (127514 bps) is located in X chromosome at Xp11.4, 
encodes for 1755 AA BCL6 corepressor protein and are known to have 4 isoforms produced 
by alternative splicing. BCL-6 corepressor function as a novel transcriptional corepressor, 
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specifically inhibit gene expression of B-cell lymphoma 6 (BCL6). BCL-6 encodes a POZ/zinc 
finger transcriptional repressor that is required for germinal center formation and may influence 
apoptosis. When BCL6 is aberrantly expressed, it leads to the development of diffuse large B cell 
lymphomas (DLBCL). The interaction of BCL6 with their novel corepressor suggests a strong 
correlation between BCOR and the oncogenic mechanism underlying the BCL-6-associated 
lymphomas [165-166]. BCOR mutations are associated with the X-linked inherited diseases Lenz 
microphthalmia and Oculofaciocardiodental syndrome [167] as well as in acute myeloid leukemia 
with normal karyotype [168]. BCOR is ubiquitously expressed in all tissues examined, including 
the spleen and lymph nodes, where BCL-6 expressing mature B cells are found. The result from 
of our immunofluorescence experiments performed on OVCAR cells is in agreement with the 
work done by Khanh D. Huynh et.al ,  2000 [165] implies their localization in nucleus. 
HIP1R is a multi-domain protein consisting of an N-terminal phospholipid binding domain 
(ANTH) which mediating phosphoinositides-interaction, a central coiled-coil, and a C-terminal 
actin-binding domain (THATCH). The coiled-coil domains of HIP1R comprise the binding site 
for clathrin light chains that regulates actin assembly and the clathrin-mediated endocytic 
machinery in cells. Isolated fragment of HIP1R constitute a region of central coiled-coil domain. 
Inside the cell, they are mainly localized at the endocytic compartments and in the perinuclear 
region. HIP1R has been previously described as a specific binding partner of BCL2L10 and 
induces BAK-dependent Cell Death [169-170]. In 2009, a study conducted at Medical University 
of Vienna, Austria [171] to define a gene signature in chronic lymphocytic leukemia (CLL) 
patients with trisomy 12 lead to the identification of HIP1R. HIP1R is considered as the best 
potential surrogate marker for +12 in CLL. Expression of this gene has a high sensitivity and 
specificity for detection. HIP1R identified as antigens associated with a colon cancer-related 
serological response [172], reacted exclusively with serum IgG derived from colon cancer patients 
but not with serum IgG from normal controls. 
In 2002, Kimmo Porkka et.al identified a 31 AA peptide identical to nucleosomal binding domain 
present in the N-terminal part of HMGN2 protein. When internalized, this peptide binds to the 
nuclei of tumor cells and tumor endothelial cells in vivo. This nuclear-targeting capability of the 
peptide could be utilized to deliver anti-cancer drugs that can act in nucleus [173]. Further Xiong 
Wen-bi and colleagues in 2008 coupled pseudomonas exotoxin domain III with the same HMGN2 
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fragment. The in vivo anti-tumor activity of this recombinant chimeric protein was determined in 
female Balb/c nude mice bearing HeLa tumor cells. Chimeric protein significantly inhibited the 
growth of xenograft HeLa tumor in nude mice. Remarkable necrosis and apoptosis of tumors were 
seen in treated mice. This peptide has the potential to be used as a novel toxin-carrier in the study 
of cancer targeting therapy [174]. 
Olfactomedin 4 (OLFM4) gene is located on chromosome 13q14.3. Often deletion of this gene is 
associated with the progression of human prostate cancer [175]. They has been also reported that 
OLFM4 promotes the proliferation of pancreatic cancer cells by favoring the transition from the S 
to G2/M phase. In myeloid leukemic cell lines, inhibits cell growth and induces cell differentiation 
and apoptosis. It may play a role in the inhibition of EIF4EBP1 phosphorylation/deactivation. It 
facilitates cell adhesion, most probably through interaction with cell surface lectins and cadherin. 
OLFM4 was identified as a novel secreted protein in head and neck squamous cell carcinoma 
(HNSCC). It was found to be overexpressed in 75% the tested cases of HNSCC, thus making them 
a potential marker of this disease [176]. Aberrant expression of OLFM4 has been primarily 
reported in tumors of the digestive system as well as association of OLFM4 expression mediated 
by estrogen receptor signaling was found to promoted the malignant progression of endometrioid 
adenocarcinoma [177]. The isolated OLFM4 fusion epitope is predicted to be a transmembrane 
protein. KIAA1755 is an uncharacterized protein.   
11.4 Validation of novel putative antigens 
We validate each of the eight most immunoreactive antigens (Table 12) individually by ELISA for 
the presence of anti-antigen antibodies in ascitic fluids collected from patients with various disease 
conditions. A total of 153 IgG purified ascites that includes ovarian cancer patients (69), other 
cancer (34) and non-cancerous controls (50) against these identified antigens were tested by 
ELISA. Each of the eight novel putative antigens has shown to produce a statistically significant 
difference in immunoreactivity between ovarian cancer patients and controls as reported in figure 
27.  As observed by protein arrays, the specificity of these eight proteins was very high, ranging 
from 94% to 100%. Sensitivity was more variable, with the highest value (86.95%) obtained for 
CREB3, least effective was HMGN2 with 18.84%. The Sensitivity and specificity attained for 
each antigens individual antigen are summarized in table 13. However, CRB3, MRPL46, BCOR 
and OLFM2 were the only antigens capable to differentiate ovarian cancer from patients suffering 
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other cancer. This remarkable feature of these antigens has to be further evaluated for their 
usefulness to predict metastatic potential of the ovarian cancer or their correlation with metastasis. 
Our panel of 8 tumor associated antigen were able to detect the majority of samples as positive 
which originated from ovarian cancer patient at least by once with any of the 8 antigen. It has 
already been described that a combination of multiple markers can increase the sensitivity of 
detection. A combined sensitivity of 88.4% with a specificity of 94-100% was achieved from this 
assay. We have identified and validated eight TAA which have never been reported in the context 
of ovarian cancer. We currently continue our work to analyze the expression level of these 
identified antigenic genes in comparison with the level and distribution of protein produced as well 
as to understand how they are correlated in eliciting immune response. Further studies are required 
to determine important information on the role played by these molecules and the pathways they 
are involved in the development and regulation of ovarian cancer.  
Moreover, the phage display library screening facilitates enrichment of the clones carrying same 
cDNA as well as selection of overlapping sequences of varying length sharing same epitopes. As 
expected, this phenomenon was clearly observed in view of the fact that multiple copies of BCOR 
clones were immunoscreened. On further analysis of these BCOR clones it was noticed that they 
occur in varying length with an overlapping epitope in common. All forms of BCOR were 
expressed and ELISA was performed with BCOR proteins of varying length. D5 Short BCOR was 
found to be recognized by most number of ascitic fluid [data not shown], leading to the 
identification of restricted epitopes. 
Finally, we confirmed whether any of the top immunogenic antigens had a prognostic value for 
cancer survival. It was seen that patients who overexpress any of the three antigens or produce 
high titer of antibody against CREB3, MRPL46 or EXOSC10 have a prolonged overall survival. 
Our data from the survival analyses stratified for antibody responses against each of these antigens 
rise the possibility that serologic detection of tumor specific antibody of ovarian cancer patient 
with favorable prognostic potential. A thorough investigation to exploit the diagnostic potential of 
these identified TAA’s has to be carried out. Validation with serum sample from same set of 
patients used for this study as well as the diagnostic capability of these antigens to detect of 
autoantibodies in serum from early stage ovarian cancer patients will have to be assessed. In 
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addition, the reactivity of autoantibodies from ovarian disease other than cancer should be 
compared to determine the diagnostic power.  
As a matter of fact, all 8 identified antigens are confined inside the cells. This situation may be 
justified, as cell surface protein accounts for only 1% of the total cellular protein giving a 
probability to identify 1 surface antigen from 100 isolated clones. In fact, the magnitude for 
isolation of surface antigen tremendously reduce as 100 clones were randomly picked from 105-
106 phage display selected clones. However, intracellular localization of these antigens may have 
several advantages. These intracellular tumor-associated antigens may elicit a very early host 
immune response in course of tumor development. This feature of antibody targeting intracellular 
antigen could apparently be used for cancer vaccines as well as to develop biomarkers that are 
capable of measuring varying level of autoantibodies which are stable and abundant even at the 
early stage of tumor in reasonably short time [110]. During tumor progression, cancer cells tend 
to shed extracellular protein thus making intracellular proteins a better choice for antigen-induced 
antibody therapies.  A reduction in cross reactivity and minimal side effects can be achieved by 
using epitope based peptide vaccine, thereby increasing the specificity [193]. 
The interest in using of anti-TAA antibodies as serological markers for cancer diagnosis derives 
from the recognition that these antibodies are generally absent, or present in very low titers, in 
normal individuals and in non-cancer conditions [194,195]. Their persistence and stability in the 
serum of cancer patients is an advantage over other potential markers, including the TAAs 
themselves, which are released by tumors but rapidly degrade or are cleared after circulating in the 
serum for a limited time [48]. Furthermore, the widespread availability of methods and reagents 
to detect serum autoantibodies facilitates their characterization in cancer patients and assay 
development. However, in contrast to autoimmune diseases, where the presence of a particular 
autoantibody may have diagnostic value, cancer-associated autoantibodies, when evaluated 
individually, have little diagnostic value primarily because of their low frequency. We have 
observed that this drawback can be overcome by using mini-arrays of carefully selected TAAs, 
and that different types of cancer may require different TAA arrays to achieve the sensitivity and 
specificity required to make immunodiagnosis a feasible adjunct to tumor diagnosis [144]. The 
reactivity of autoantibodies against post-translational modified isoforms of these identified 
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proteins should be evaluated. This assay could be facilitated by 2-dimensional separation of 
ovarian cancer cell proteome followed by identification of reactive protein by mass spectrometry. 
The data presented in our study demonstrates the capability of our approach in biomarker 
discovery and has a great potential to develop diagnostic marker for the early detection of ovarian 
cancer. With this approach we have identified and validated eight different tumor associated 
antigens, which includes CREB3, MRPL46, BCOR, HMGN2, HIP1R, EXOSC10, OLFM4 and 
KIAA1755 with a key role in tumor regulation.  We believe that identification of more TAAs could 
help in better understanding of the molecular pathology involved in cancer development and 
progression. Understanding the physiological activators, interactors and targets of these identifies 
TAA’s will derive new knowledge in transcriptional regulation and new strategies in the 
intervention of human diseases. We conclude that the proposed approach represents a valid 
strategy to high-throughput profiling ascetic fluid from ovarian cancer patients. 
11.5 Tumor regulation mediated by cell surface tumor antigen targeting antibodies 
The latter part of this project demonstrated the presence of autoantibody in ascites targeting cell 
surface antigens expressed by tumor cells and verified its role in controlling tumor growth by 
activating complement. The meaningful targets for immune responses are mainly domains of 
surface-expressed proteins and glycoproteins that are accessible to antibodies and cytotoxic 
immune cells [150]. Our immunofluorescence assay illustrates the presence of tumor specific 
surface antigen on live ovarian cancer cell line.  The cell surface staining was performed with the 
same set of antibodies on ovarian carcinoma cells while incubating them on ice. The result we 
have obtained implies the presence of cell surface receptor. Antibodies binding to these specific 
receptor gets internalised by endocytosis or pinocytocis [196,197]. Another possibility could be 
that some of the intracellular antigens or proteolytic fragments of intracellular target might get 
externalised and displayed on the surface of cancer cells by unconventional secretion [152]. 
Further, cell surface ELISA was performed for the identification and localization of target antigens 
as well as the quantitative analysis of cell surface antigen expression. This technique enabled for 
the quantification of immunoreactive antibodies present in samples targeted specifically against 
tumor associated antigens expressed by immobilized/ adherent OVCAR3 cell on their cell surface 
[144].  
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It was also evident from our result that the complement system plays a vital role in regulation of 
tumor. The cytotoxic C activity in ascitic fluid was examined by exposing OVCAR cells to 
immunoglobulins purified from ascetic fluids. Normal human serum was used as a control source 
of C in the cell-killing assay. Maximal killing (25-30%) of OVCAR3 cells was obtained by treating 
them with a mixture of cMOV18 and cMOV19 was set as a positive control for this assay. Almost 
75% of Cell surface ELISA positive samples collected from primary ovarian cancer patients was 
able to induce complement dependent killing of OVCAR cells (Fig 31). The antibody from 
noncancerous patients were not competent enough to cause any killing. This may be due to the 
fact that the absence of particular antibodies which might be required for complex formation to 
activate the complement pathway. Presence of C regulators might be another reason for 
constrained C-dependent lysis of these cells.  
In this present study, we have verified the presence of tumor specific immunoglobulins in ascitic 
fluid collected from ovarian cancer patients directed against surface antigens and demonstrated 
that these molecules are capable to activate the complement system on binding to their cell surface 
antigen/ receptor followed by a cascade of events leading to C mediated killing of tumor cells. 
Hence, we would strongly suggest this as an effective immunological surveillance mechanism in 
regulation of tumor. In the case of ovarian cancer, the presence of tumor cells within the peritoneal 
cavity surrounded by a functional C system also makes this tumor type an attractive target for local 
monoclonal antibody therapy [50]. Isolation of cell surface tumor associated antigens and 
identifying them by mass-spectrophotometry will be another prospective aspect of this study. 
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Chapter 4 
12. Conclusion  
The strategy proposed within this work provides a systematic profiling of ovarian cancer ascites 
by coupling phage display to high-throughput screening technologies. This new valuable tool 
could be applied to obtain selection of tumor associated antigens with potential diagnostic value 
or biological relevance in any auto-antibody-antigen related pathologies such as cancer, 
autoimmune and various infective diseases. Beyond the advantage in identifying new 
antigens/autoantigens that can provide insights into the pathogenesis of the diseases studied, 
diagnosis and prognosis as well can be improved. Our approach could provide information about 
the pathological subtypes, recognize the state in the early stages of its development, specific 
antibody signatures produced by each patients which could be correlated with the survival. These 
great deal of information may anticipate the therapeutic intervention, thus avoiding or delaying the 
pathological manifestations. 
In addition, our approach allows to focus the attention on the desired target (i.e. the specific organ 
or tissue), and screening its whole specific proteome, by isolating mRNA (representing all 
expressed genes) and cloning in an appropriate system. The possibility to select proteins (i.e. for 
their binding capability), provided by the phage display system, allows the enrichment for target 
proteins, decreasing the number of proteins to be assayed, enables the identification of the 
interactors/ molecular signature of disease from a high degree of complexity and present in low 
abundance with high sensitivity. Thus, overcoming the major limitations usually encountered in 
these systems when used separately. At the same time, the link with the genotype permits the rapid 
identification of the reactive polypeptides. In this regard, this global approach is proposed as a 
general tool the dissection of complex molecular interaction systems. 
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Chapter 5 
13. Materials and Methods 
13.1 Section 1  
Abbreviations: 
Ab, antibody 
AP, Alkaline Phosphatase  
BCIP, 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside  
B-PER, bacterial protein extraction reagent  
BSA, Bovine Serum Albumine  
DMSO, Dimetilsulfoxide  
dNTPs, deoxynucleotides  
DTT, dithiothreitol  
GSH, glutathione 
HRP, HorseRadish Peroxidase  
IPTG, Isopropyl β-D-1-thiogalactopyranoside  
NBT, NitroBlue Tetrazolium  
NC, nitrocellulose 
O/N, over night 
PBS, phosphate buffered saline 
PEG, polietilenglicole   
RT, Room Temperature  
TMB, Tetrametilbenzidine 
ZYM5052, autoinducing medium 
 
13.2 Section 2 
Solutions and buffers 
 PBS 
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 in 1000 mL H2O, final pH 7.4. 
 TAE buffer for DNA electrophoresis on agarose gels 
0.04 M Tris-acetate, 0.001 M EDTA. 
 2xTY liquid broth for bacteria 
16 g Bacto-tryptone, 10 g Bacto-yeast, 5 g NaCl, final pH 7.0. If required, ampicillin 100 μg/mL, chloramphenicol  
34 μg /mL, streptomycin 75 μg /mL 
 ZYM5052 liquid broth for bacteria 
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Freshly prepared by adding each sterile stock solution in the following order: 80% ZY (10% Tryptone, 5% Yeast 
extract); 50x M (1.25M Na2HPO4, 1.25M KH2PO4, 2.5M NH4Cl, 0.25M Na2SO)4; 2mM MgSO4; 100ox Metal Mix 
(50 mM FeCl3, 20mM CaCl2, 10mM MnCl2, 10mM ZnSO4, 2mM CoCl2, 2mM CuCl2, 2mM NiCl2, 2mM Na2MoO4, 
2mM Na2SeO3, 2mM H3BO3); 50x 5052 solution (25% glycerol, 2.5% glucose, 10% α-lactose monohydrate); 100 
μg/mL of ampicillin, sterile water to volume.  
 2xTY Agar plates 
16 g Bacto-tryptone, 10 g Bacto-yeast, 5 g NaCl, 15 g Bacto-agar, final pH 7.0. If required, ampicillin 100 μg/mL, 
chloramphenicol  34 μg /mL, streptomycin 75 μg /mL. 
 CCMB80 for preparation of competent E.coli cells 
11,8 g CaCl2 (dihydrate), 4,0 g MnCl2 (tetrahydrate), 2,0 g MgCl2 (hexahydrate), 10mM K-acetate (pH7), 10%  
Glycerol, H2O to 1L. Adjust pH to 6.4 . Filtration with 0.2 μm filter. 
Glycerol Buffer for preparation of electrocompetent E.coli cells 
10% glycerol in milliQ water. Autoclave before use. 
 PBST 
PBS added with 0.1% Tween 20 
 MPBS 
PBS added with 2% non-fat milk powder. 
     
Bacterial strains 
The bacterial strains used in this study were: 
- Escherichia coli DH5αF’ (Gibco BRL), F’/endA1 hsd17 (rK− mK+) supE44 thi-1 recA1 gyrA (Nalr) relA1 _ 
(lacZYA-argF) U169 deoR (F80dlacD-(lacZ)M15) 
- Escherichia coli BL21-CodonPlus(DE3)-RIPL strain B F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ(DE3) endA Hte 
[argU proL/Camr] [argU ileY leuW Strep/Specr] 
 
Oligonucleotides for general screenings 
All primers were purchased from Biomers. 
 
 
 
 
 
 
Table 14: Oligonucleotide sequences 
 
 
 
Oligo ID Sequence (5’-3’) 
VHPT2 antisense TGGTGATGGTGAGTACTATCCAGGCCCAGCAGTGGGTTTG 
VLPT2 sense TACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTC 
pGEX sense GGGCTGGCAAGCCACGTTTGGTG 
pGEX anti CCGGGAGCTGCATGTGTCAGAGGTTTTCACC 
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13.3 Section 3 
Standard protocols used 
PCR (Polymerase chain reaction) 
Thermus aquaticus DNA polymerase (Finnzymes) was used. 
Reaction mixture: 
 Template DNA                    0.01-1 ng (plasmidic DNA) 
 Sense primer        0.5 μM 
 Antisense primer                      0.5 M 
 Finnzymes Buffer 10x                                2.0 L 
 dNTPs  (Promega)        0.25 mM 
 MgCl2          1.5 mM 
 Taq polymerase                       0.025 units/L 
 H20            to 20 L 
The following cycles were performed: 
 Denaturation step, 5’ at 94°C. 
 31 cycles of: denaturation, 45’’ at 94°C; annealing, 45’’ at 60°C; elongation, 1’ every 1000bp at 72°C. 
 Final elongation step: 10’ at 72°C  
Inverse PCR 
Reaction was performed on plasmidic preparations as follows of the libraries subcloned in pGEX vector: 
 DNA (10 ng)                                         1   μL  
 Primer sense  (0,5 uM)                             1   μL 
 Primer anti     (0,5 uM)                             1   μL 
 Buffer HF (5x)                                       4   μL 
 dNTPs            (0,4 mM)                        0.4 μL 
 Fusion Pfu polymerase (Finnzymes)                   0.2 μL  
 H2O                                                   to 20  μL 
 
PCR amplification was performed as follows: 
Initial denaturation 
 30’’ at 98°C 
31 cycles as follows: 
 10’’ at 98°C 
 10’’ at 70°C  
 1’15’’ at 72°C (15’’/kb) 
Finale extension: 5’ at 72°C 
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Amplicons were gel-purified and 10 ng of the purified product were ligated O/N at 16°C. After transformation in 
E.coli competent cells, cultures were plated onto ampicillin containing agar plates. After O/N growth at 28°C, colonies 
were screened by PCR with pGEX specific primers. 
DNA electrophoresis on agarose gels 
Agarose (Sigma) gels with a concentration of 1.5 % in TAE buffer were used to separate PCR products; 0.8 % agarose 
gels were used to separate plasmidic DNA preparations, before and after digestions. 1 μL of ethidium bromide 
(2mg/mL, Sigma) was added to 50 ml of agarose gel. 
100 base-pairs plus and 1KB molecular weight markers were purchased from Fermentas. 
DNA purification 
The NucleoTraPCR kit (Macherey-Nagel) was used for purification of DNA from agarose gel and reaction mixtures,  
following the manufacturer instructions. 
Plasmidic DNA extraction 
The Perfectprep Plasmid kit (Eppendorf) was used for plasmidic DNA mini-preparations (1 to 5 ml of O/N bacterial 
culture), following the manufacturer instructions. 
DNA digestion with restriction endonucleases 
All restriction endonucleases (BssHII, NheI) were purchased from New England Biolabs. 
Reaction mixture: 
 DNA 
 NEB Buffer 10x 
 BSA 100x 
 Restriction endonuclease, 1 unit / μg of DNA  
 H20 to 50 L 
Incubation for 1 hour at the temperature required by the specific endonuclease. 
Ligation 
Plasmidic vector DNA and insert DNA were mixed at a 1:3/1:5 ratio (number of molecules). T4 ligase was purchased 
from New England Biolabs. 
Reaction mixture: 
 DNA (about 100 ng) 
 T4 ligase Buffer (NEB) 10x 
 T4 ligase (NEB), 1 Unit/reaction  
 H20 to 10 L 
Incubation O/N at 16°C. 
Preparation of competent E.coli 
50 mL of E.coli culture, DH5α or BL21(DE3)RIPL strains, were grown at 37°C in 2xTY liquid broth to OD600 0.5. 
Bacteria were chilled in ice for 10’ to stop growth, centrifuged at 4°C for 10’ at 3000 rpm and the supernatant was 
discarded. The bacterial pellet resuspended in 8 mL of CCMB80 solution and put in ice for 20’. After centrifuging for 
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10’ at 4°C, supernatant was discarded, bacterial pellet resuspended in 2 mL of CCMB80 and dispensed in 80 μL 
aliquotes. Competent cells were immediately used or stocked at -80°C  up to four weeks. 
Bacterial transformation 
5 μL of ligation reaction mixture or 10-50 ng of plasmidic preparation were transferred into a tube containing 80 L 
of competent cells. The mixture was incubated in ice for 20’. Heat shock was applied at 42°C for 1 minute and 15’’; 
bacteria were then chilled in ice for 2 minutes, resuspended in 1 ml of liquid broth and allowed to grow in absence of 
selective antibiotic for 1 hour. Bacteria were then plated on antibiotic-containing agar plates and grown O/N at 30°C. 
Preparation of electro-competent E.coli cells 
The following protocol was used for preparation of E.coli DH5α F’ electrocompetent cells. 
 Grow E.coli DH5α strain in 200 ml of 2xTY liquid broth to OD600 0.8. 
 Split the culture in 4 50ml-tubes and put on ice for 20’. 
 Centrifuge at 5,000 rpm, at 4°C for 8’. 
 Discard the supernatant and gently resuspend the pellet with glycerol buffer. 
 Add glycerol buffer to 50 ml and incubate 10’ on ice. 
 Centrifuge at 5,000 rpm, at 4°C for 10’. 
 Discard supernatant, resuspend pellet with glycerol buffer and collect in two 50-ml tubes. 
 Add glycerol buffer to 50 ml and incubate 10’ on ice. 
 Centrifuge at 5,000 rpm, at 4°C for 10’. 
 Discard supernatant, resuspend pellet with glycerol buffer and collect in one 50-ml tube. 
 Add glycerol buffer to 50 ml and incubate 10’ on ice. 
 Centrifuge 5000rpm per 10’ a 4°C. 
 Discard completely the supernatant and resuspend the pellet with 125 µl of glycerol buffer for every 100 ml 
of bacterial culture. 
 Use immediately or stock at -80°C for up to four weeks. 
To test the efficiency of the so prepared cells an electroporation of 10 pg of purified commercial pUC119 vector was 
performed. The efficiency was generally about 1010 transformed clones / μg DNA. 
DNA Sequencing 
PCR products were purified with Eppendorf  Perfectprep Gel Cleanup kit following manufacturer instructions.  
Reaction mixture for sequencing were composed as follows: 
 50-100 ng of purified PCR product 
 1 μL primer (3,2 μM) 
 2 μL Terminator Mix (Applied Biosystems, BigDye Terminator v1.1 Cycle Sequencing Kit) 
 2 μL buffer 5x 
 H2O to 10 μL 
and the sequencing program was:  
 1’ at 96° 
 25 cycles: 15’’ at 96°; 5’’ at 50°; 4’ at 60° 
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Reactions were purified with CENTRI SEP Spin Columns, following manufacturer instructions. 5 μL of purified 
sequences were loaded on sequencing plates with 10 μL of formamide, denaturated for 2’ at 96° and analyzed with 
3100 Genetic Analyzer sequencer (ABI PRISM-HITACHI). 
13.4 Section 4: Methods 
13.4.1 Patient samples and cell line 
  
13.4.1A Sample preparation 
 
Ascites were collected from 153 patients representing various disease conditions which include ascites from patients 
diagnosed with ovarian cancer (69), other cancers (34) and non-cancerous control ascitic fluid (50) from female 
patients with no known history of cancer. Numbers in brackets indicate the number of patients for each group. Ascitic 
fluid samples were obtained from i) the Department of Clinical and Experimental Medicine, University of Eastern 
Piedmont, ii) Department of Life Science, University of Trieste, iii) Istituto Nazionale Tumori, Milan and iv) 
University of Turin. All ascite samples were centrifuged at 11000 rpm at 4oC for 5minutes and supernatants were 
stored at -80oC until processing. Immunoglobulins from all ascitic fluid were affinity purified using Protein A Agarose 
(Roche). 50µl of crude ascitic fluid was mixed with starting buffer containing 100mM TRIS-HCl pH 8, 1% IGEPAL 
CA630, 1mM EDTA, 1mM PMSF, 1:100 dilution of protease inhibitor, 40µl Protein A agarose in a final volume of 
1ml. Incubated overnight at 4oC on a rotating platform. Washed and eluted to an equal volume of sample used with 
100mM glycine pH 2.5, later added 20% 1M TRIS –HCl pH 8 for stability. 
13.4.1B Cell lines 
The human ovarian adenocarcinoma cell line (NIH: OVCAR-3, ATCC® HTB-161™) was grown in RPMI 1640 media 
containing 10% foetal calf serum, 2 mM glutamine, and 1% penicillin/streptomycin. Cells were maintained at 37°C 
in a humidified atmosphere containing CO2.  
 
13.4.2 Characterization of ascitic fluid based on autoantibody response 
 
13.4.2A Western Blot of OVCAR-3 Cell Extract  
Western blot was performed to confirm the presence of tumor specific antigens present in OVCAR-3 cell extract. 
OVCAR-3 cell extract was prepared under denaturing condition using 8M Urea. After 1hr blocking step with 4% 
MPBST, 1:50 dilution of antibodies isolated from ascites fluid from 20 patients were used as the source of primary 
antibodies. These samples were diluted in 2% MPBST and incubated at RT for 45 min. Membranes were incubated 
1.5 hrs RT and followed by 1 hr incubation with secondary antibody, alkaline phosphatase conjugated anti-human 
IgG.  The membrane was developed using chromogenic substrate (NBT/BCIP, Roche). 
 
13.4.2B Ovarian Cancer Whole Cell ELISA 
OVCAR-3 cells were seeded in 96-well culture plates at a density of 1 × 104 cells/well and incubated 24 hrs at 37 °C 
in presence of CO2. Plates were subsequently washed 3 times with wash /blocking buffer (1M MgCl2, 1M CaCl2, BSA 
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(FC 2%) in PBS), fixed and permeabilized with methanol. After incubation on ice for 5 min, methanol was discarded 
and washed twice with wash /blocking buffer. Plates were incubated for 1.5 hr on ice at 40 C with 100 μl pre-blocked 
primary antibody (Purified and normalised Ascitic IgG)/well which were diluted 1:100 in wash /blocking buffer. The 
plate was subsequently washed 3 times with blocking buffer and incubated for 1 hr on ice at 40C with 1:2000 dilution 
of peroxidase-conjugated secondary antibody in blocking buffer (Polyclonal Rabbit Anti-Human 
Immunogulobulins/HRP; Dako). Performed 3 washes and dried. 70μl of TMB (3,3′,5,5′-Tetramethylbenzidine liquid 
substrate, Sigma ) was added to each well and dark incubate on ice until proper intensity was observed. This TMB 
was transferred into a new ELISA plate already containing 35μl 1N H2SO4 to stop the enzymatic reaction. The 
absorbance at 450 nm was measured with a microplate reader. The cutoff value was calculated as cumulative mean + 
2 (standard deviation) of the absorbance from non cancerous control wells. 
13.4.2C Ovarian Cancer Cell Lysate ELISA 
Cell extraction procedure:  Confluent OVCAR-3 cells grown in a 100mm tissue culture plate were washed gently 
with ice cold PBS. Cells were scraped out into pre-chilled tube by adding 0.5 ml of complete non- denaturing 
extraction buffer containing 100 mM Tris, pH 7.4 ; 150 mM NaCl; 1 mM EGTA; 1 mM EDTA; 1%  IGEPAL; Protease 
inhibitor cocktail (Sigma p8340) and 1 mM PMSF. Cells were briefly sonicated after incubation on ice for 15-30 min. 
The soluble cell extract were transferred into new tube following centrifugation at 13,000 x rpm for 10 min at 4°C and 
the concentration was determined by BCA assay.  
Cell Lysate ELISA: 96 well microtiter plate O/N coated with 3.2 μg/well of OVCAR-3 cell extract was blocked with 
2% BSA in PBST (0.05%) for 1hr at 30°C. The plate was incubated for 1.5 hrs at 30oC with 100 μl primary antibody 
(1: 50 diluted purified ascitic IgG preblocked for atleast 30 min). The unbound antibodies were removed by washing 
with PBST (0.05%) and PBS 1x. Incubated for 1hr at 30°C with 1:5000 diluted anti-human IgG/horseradish peroxidase 
conjugate in each well and subsequently washed. 70 μL of 3,3′,5,5′-Tetramethylbenzidine  substrate solution was 
added and incubated in dark until a proper intensity of colour was observed. The reaction was stopped by adding 35 
μL/well of 1 N H2SO4.  Plates were read spectrophotometrically at 450 nm. 
13.4.2D Immunofluorescence Assay 
5 x 104 OVCAR cells were plated onto poly-L-lysine-coated glass coverslips in a 10cm cuture plate without any 
overlap. The culture was incubated at 37oC in presence of CO2 until they attains 80% confluence. This culture plate 
was washed once and the cover slips were transferred individually to new wells of 24 well culture plate.  
OVCAR Cells Surface Staining: The confluent cells on the cover slips were washed once with plain RPMI and 1: 
10 diluted primary antibody in blocking buffer (5% BSA in serum free RPMI medium) was added. Incubated on ice 
at 4oC for 2 hrs. After primary incubation, the unbound antibodies were removed by washing 3 times with blocking 
buffer. The cells transferred to new well and were subsequently incubated for another 1 hr on ice at 4oC with secondary 
antibody (anti hIgG- cy5) diluted 1:200 in blocking buffer. Performed 2 washes, transferred them to new wells in 
which the cells  were fixed with 200μl of 4% PFA + 4% Sucrose on ice for 15 min, and permeabilised the cells for 2-
3min 0.2% triton in PBS. The fixed and permeabilized cells were incubated with 1:2000 dilution of propedium iodide 
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(PI: nuclear stain) in PBS. Cells were washed thrice with PBS 1x and once with dH2O, mounted to a glass slide with 
a small drop of mountant and the cells on cover slip facing the mountant and sealed with nail polish. The cells were 
directly analyzed with a Leica TCS-SP confocal laser scanning microscope using sequential scan tool. Laser power 
and photomultiplier settings were kept identical for all the samples to be able to compare the results. 
 
Fixed and permeabilized OVCAR Cells for intracellular staining: The confluent cells on the cover slips were 
washed twice with prewarmed phosphate-buffered saline (PBS). The cells were fixed with 200μl of 4% PFA + 4% 
Sucrose on ice for 15 min, and permeabilized the cells for 2-3min 0.2% triton in PBS. The fixed and permeabilized 
cells were washed once with RPMI and 1: 10 diluted primary antibody in blocking buffer (5% BSA in serum free 
RPMI medium) was added. After 2hr incubation at 37oC, the unbound antibodies were removed by washing 3 times 
with blocking buffer. The cells transferred to new well and were subsequently incubated for another 1 hr 37oC with 
secondary antibody (anti hIgG- cy5) diluted 1:200 in blocking buffer. Performed 2 washes, transferred them to new 
wells in which the cells were incubated with 1:2000 dilution of propidium iodide (PI: nuclear stain) in PBS. Cells 
were washed thrice with PBS and once with dH2O, mounted to a glass slide with a small drop of mountant and the 
cells on cover slip facing the mountant and sealed with nail polish. The cells were directly analyzed with a Leica TCS-
SP confocal laser scanning microscope using sequential scan tool. Laser power and photomultiplier settings were kept 
identical for all the samples to be able to compare the results. 
 
13.4.3 Selection of cDNA Phage Display library 
13.4.3A Phage production 
An aliquot of the bacterial stock of the library was thawed from the -80°C freezer and diluted in 10 mL of 2xTY liquid 
broth added with chloramphenicol/ampicillin in order to have a starting OD600 around 0.05. Bacteria were grown in a 
100 mL flask shaking at 220 rpm and at 37° C, to OD600 0.5. Bacteria were infected with a wild-type helper phage 
(M13K.07) at a MOI (molteplicity of infection) of 20, at 37°C for 45 min, without shaking. After infection, bacteria 
were centrifuged at 1500 x g for 10 min at 30° C, the supernatant was discarded and the pellet resuspended in 40 mL 
of 2xTY broth added with chloramphenicol/ampicillin and kanamycin (helper phage resistance). Bacteria were then 
grown O/N, at 30° C and shaking at 220 rpm, to allow production of the recombinant phages in the culture supernatant.  
The following day bacteria were centrifuged at 7,000 rpm for 20 min at 4° C. The phages-containing supernatant was 
collected and precipitation was performed by adding 10 mL (1/5 of total volume) of PEG-NaCl solution ( 20% PEG-
8000 (Fluka) in 2.5 M NaCl, filtered with a 0.22 μm filter before use) and incubating on ice for 45 min. The solution 
was then centrifuged at 7,000 rpm for 20 min at 4° C, to collect the phages; the supernatant was carefully and entirely 
discarded and the white pellet was resuspended in 1 mL of PBS. The solution was centrifuged for 5 min at 10,000 
rpm, to pellet the remaining bacteria in solution; the phage-containing supernatant was then transferred into a fresh 
tube and kept in ice until needed. 
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13.4.3B Phage Display Library Selection 
Phage selections were performed as described in Di Niro et al, 2009 [147]. Bacterial stock of library (Human ORF 
libraries from pancreatic islets (HPI), colon cancer (HCC) and lung fibroblasts (HF)) was grown and infected with 
wild type helper phage (M13k.07) for replication and recombinant phages were collected. Phage selection and 
enrichment using G-protein functionalized magnetic beads (Dynabeads) coated with ascite IgG.  
Ascite antibodies were coupled to M450 Magnetic beads (Dynabeads) as follows: dynabeads were resuspended 
and 10 μl of beads were transferred to a microcentrifuge tube; two washes were performed with 0.5 ml of acetate 
buffer, pH 5. 5 μl of purified ascite antibody, diluted in 100 μl of PBS were added to the beads, and incubated for 45’ 
in rotation at RT. Beads were washed 3 times with acetate buffer pH 5 to remove unbound antibodies and other 
proteins.  
Subtraction step: First a pre-clearing step for the removal of the non-reacting phages by incubated with negative 
bead preparation, ie coated with IgG healthy serum to avoid any sort of background. This was performed by adding 
200μl of PEG-precipitated phages (10
11 
phages) to the beads functionalized with sera from healthy donors, and 
incubated for 30’ in rotation. Magnetic field was then applied, so that the bound phages were washed away, while the 
unbound phage population was collected and incubated with the beads functionalized with ascite antibodies from 
ovarian cancer patients, and incubated for 90’ in rotation.  
The selection procedure was performed as follows: Subtraction step was followed by 2 rounds of selection to enrich 
bound peptide sequence by separate incubation with seven different IgG purified primary ovarian cancerous ascites. 
0.2 mL of phage preparation, containing 1011 phages, were added with an equal volume of 4% MPBS and incubated 
for 1 hour at RT. The phages were then incubated with the beads coupled to antibodies from sera from healthy donors, 
for 30 min in rotation at RT. The supernatant was collected by applying a magnetic field to remove the beads and the 
bound phages. The phages were then incubated with the beads coated with antibodies from the ascitic fluids collected 
from ovarian cancer patients, for 90 min in rotation at RT. Washes were performed by adding 1 ml of PBST or PBS 
to the beads, and then by applying a magnetic field to remove the solution with unbound phages. The stringency of 
the washing steps increased with the selection rounds; 10 times with PBST and 10 times with PBS for the first round 
of selection, 15 and 15 for the second, 15 and 15 with additional 10 min with rotation in PBST in the between for the 
third. After the washing steps, bound phages were eluted by mixing the beads with 1 mL of E.coli DH5α, at OD600 
0.5, at 37° C, for 45 min, with occasional shaking. Bacteria were plated on 15 cm 2xTY agar plates added with 
chloramphenicol and grown O/N at 30° C. Bacteria are harvested and either grown immediately to undergo the 
following round of selection or stored in small aliquots at -80° C. 
13.4.3C Subcloning of cDNA fragments in pGEX bacterial expression vector  
The modified pGEX vector (GE Healthcare) was used.  
Plasmid preparation of the selected library was obtained from an aliquot of bacteria after third cycle of selection and 
digested using restriction sites flanking the cDNA gene fragments (BssHII – NheI). The digested fragments in the 
100-700 bp range were purified and ligated to the vector cut with the same enzymes. The ligation reaction (vector : 
insert molar ratio of 1:5) was purified and transformed into DH5αF’ E.coli strain. 
The resulting mini-library size was around 105 clones. 
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13.4.4 High-throughput recombinant protein production of the selected clones in autoinducing medium 
After immunoscreening, the selected cDNA fragments were subcloned into an expression vector, a modified pGEX 
Vector and amplified in the host bacteria BL21 (DE3) RIPL cells for enhanced protein production. 95 single clones 
from each of the 7 selections were randomly picked from agar plates and inoculated into 96 deep well plates in order 
to produce GST fusion protein. Protein production was carried out by auto inducing medium ZYM5052   [148] in 96 
wells format and grown overnight at 28°C. Purification of recombinant proteins was done using GSH magnetic beads. 
The production and purification of this fusion protein were analysed by SDS-PAGE and western blotting with few 
random samples. Full length fusion protein were identified by incubating nitrocellulose membrane with 1:5000 
dilution of αFLAG primary antibody and screening with alkaline phosphatase-conjugated anti-human IgG secondary 
antibody. 
13.4.5 Immunoscreening of the selected antigen by protein microarray 
The immunoreactivity of the phage display selected antigens were determined by microarray analysis. With the aid of 
BioOdissey Calligrapher (Biorad) all the purified GST-fusion proteins were spotted onto a nitrocellulose (NC) slide. 
The purified proteins along with the controls (dilution rows of purified human IgG (Sigma), ranging from 500 ng/mL 
to 100 μg/mL) were printed in duplicate in two identical fields of the same slide maintaining all parameters (such as 
contact time, distance between spots, wash cycle) and conditions including 15oC temperature and 50% humidity. The 
slides were incubated for 1hr at room temperature (RT) with blocking buffer (3% non fat dry milk in PBS 0.1% 
Tween20 (3%MPBST)).  Once the sides were saturated, each of the 2 identical fields was incubated with 1:50 dilution 
for primary antibody (acitic fluid from cancer patients, non-cancerous patients, also anti-GST and Anti-FLAG 
monoclonal antibody against the fusion Tag) in 2% MPBST for 1.5 hrs. The slide assayed with Anti-GST and Anti-
FLAG ensures that the proteins a properly spotted on to the slide. Performed 2 washes with PBST for 15 min and once 
with PBS. Added 1:200 diluted secondary antibody, Cy5 conjugated anti-human IgG - Cy5 conjugated (anti-mouse 
IgG for the slide incubated with anti-GST and Anti-FLAG) in 2% MPBST and incubated at RT for 1 hr. Cy5 is highly 
sensitive even with very low amount of autoantibody and stable fluorophore which gets excited at 650 nm wavelength. 
Washed twice with PBST and once with PBS, 5min for each washing step and dried. All fluorescent signals were 
detected with a ScanArray Gx®, PerkinElmer scanner and analyzed with ScanArray Expression Software, 
PerkinElmer. The fluorescence intensity of each feature was determined, based on the mean of pixels’intensity within 
the protein feature minus the mean intensity of pixels in the surrounding area. Optimized scanning conditions were 
used for each substrate in order to obtain maximal non-saturated signals. The sample giving highest florescent signals 
were selected for next level. 
 
13.4.6 Identification novel putative tumour-associated antigens (TAA) by sequencing  
The most immunoreactive clones identified by microarray analysis were further processed to decode their sequence. 
As the first step, these screened clones were PCR amplified using pGEX sense (GGGCTGGCAAGCCACGTTTGGTG) 
and anti-sense primers (GGTGAAAACCTCTGACACATGCAGCTCCCGG). The PCR amplified products were purified 
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using nucleo spin extract kit II (Macherey-Nagel) and the DNA fragment of varying size (150-800bp) were sequenced. 
Under optimised condition, a fluorescence based cycle sequencing reaction was performed with the purified PCR 
amplified fragments/template along with its sequence specific primer (pGEX sense or anti sense) and ABI BigDye 
Terminator v1.1. The extension products were purified using Centri-Sep Columns (Princeton separations) based on 
gel filtration. The reaction mixture was added directly on top of the hydrated illustra Sephadex fine DNA grade (GE 
healthcare) gel bed and spun down at 3600RPM. This was done to remove all the free and labelled dNTP’s and 
unwanted buffer salts. The sequencing was carried out using ABI 3100 sequencer. 
13.4.7 Large Scale Production of Novel Putative Antigens 
13.4.7A Expression and purification of selected antigen  
Microarray screened and characterized immunoreactive clones were traced back to the 96 well stock plate stored at -
80°C. The exact clones were picked from plate, were grown in 1mL of 2xTY medium at 28 ° C in a shaking platform 
for 16 hours in the presence of 2 % glucose , thus to minimize the expression from the lac promoter . The following 
day, they were moved to a larger volume and grown at 28 ° C until reaching an optical density of OD600 0.5. Protein 
induction was performed for 3 hours at 25°C with 0.1 mM IPTG ( Millipore) , which acts on the lac promoter and 
induces gene expression.  
Bacterial cultures were centrifuged at 5000 rpm for 15 minutes and the pellet was resuspended in lysis buffer (50mM 
TRIS HCl pH 7.4, 150mM NaCl, 1% IGEPAL CA630, 1mM EDTA,1:100 dilution of protease inhibitor cocktail 
P3840 sigma ) (10 mL / gram of pellet ) .  Then added lysozyme ( 1 mg / gram of pellet ) ( Fluka ) and DNAse (20-50 
g / mL ) (Sigma) and the samples were incubated for 1 hour at 4°C with gentle shaking.  At this point, sonication was 
performed in case the sample is not completely lysed, using the sonicator (Bandelin sonoplus HD2070 ) . Clarified 
lysates were centrifuged at 5000 rpm for 15 minutes. The supernatant was recovered and incubated with prewashed 
glutathione agarose (GSH) resin (Sigma). The suspension was incubated with gentle mixing on a rotating platform at 
4°C for 45 min; supernatant was applied to a filter column; column was washed twice with PBST0,1%  and once with 
PBS. Two elution steps were performed at 4°C for 15 min with 100μL of  freshly prepared elution buffer (50mM GSH 
reduced-Sigma, 100mM NaCl, PBS pH8). After incubation, the two fractions of eluted protein were collected, 
aliquoted and stored at -20°C . 
The proteins produced were later analyzed for their quality. These purified proteins were denatured, loaded and 
performed polyacrylamide gel electrophoresis.  The gels were stained with Coomassie blue or alternatively, the 
proteins were transferred onto a nitrocellulose membrane to analyzed by  Western Blot. 
 
13.4.7B Western blotting 
Western blots were performed using purified GST fusion protein. After transferring step, membrane was blocked for 
1 h at room temperature using 4% MPBST. Then incubated 90 min with 1:5000 dilution anti-FLAG/ anti-GST primary 
antibody in 2%MPBST. Subsequently were washed using PBST (0.1% v/v) and PBS 1X. Anti mouse IgG coupled to 
alkaline phosphatase (1:5000 dilution in 2%MPBST) was used as the secondary antibody. Membrane was developed 
by adding NBT/BCIP substrate. 
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13.4.8 Validation of Putative Antigenic Protein by Indirect ELISA 
Presence of a specific antibody in ascitic fluids were tested by indirect ELISA. 96 well ELISA plate was pre coated 
(O/N at 4°C) with 1μg of purified full length GST fusion protein in 100 μL of PBS was saturated with blocking buffer 
(2% BSA in PBST(0.05%)) for 1 hr at 30°C.1: 50 diluted primary antibodies in blocking buffer were incubated at RT 
for 45 min enabled with proper mixing and were subsequently transferred into their appropriate well and incubated at 
30°C for 90 min. Primary antibody used were affinity purified IgG from 153 ascites from patients which includes 
ovarian cancer, other cancer and non-cancerous control. After incubation at 30oC, the unbound primary antibodies 
were removed by washing 3 times with PBST 0.05% and PBS 1x. Incubation at 30°C for 1hr with 1:5000 dilution of 
peroxidase-conjugated secondary antibody in 2% blocking buffer. 70 μL of 3,3′,5,5′-Tetramethylbenzidine  was added 
to all well after final wash (3 times) with PBST(0.05%) and PBS 1x. The plate was incubated in dark until they have 
attained proper intensity of colour. The reaction was stopped by adding 35 μL/well of 1 N H2SO4.  Plates were read 
spectrophotometrically at 450 nm. For each antigen validation, the cut-off value was independently calculated as ‘sum 
of (cumulative mean + twice the standard deviation) of the absorbance from non-cancerous control wells. 
13.4.9 Analysis for the prognostic potential of the novel antigens and their clinical correlation  
Based on the antigen ELISA result, Kaplan meier analysis calculates the proportion surviving to each point that a 
death occurs and was done to understand the clinical correlation of overall survival of the patients with the presence 
of specific antibodies. Later, a log-rank method was used to evaluate their significance. 52 patients with at least 18 
months follow up details were used for the overall survival analysis. 
13.4.10 Verification of Cell Surface Targets by Cell Surface ELISA on Live OVCAR-3 Cell Line 
Added 100μl of 1x 104 OVCAR cells into each well of the 96-well microplates and incubate in 5% CO2 at 37° C in a 
cell culture incubator for 36hrs. The culture medium was removed from every well and washed once with 100μl RPMI 
medium containing 10 % FBS (pre warmed at 37o C). Primary antibody (Purified and normalized ascitic IgG) were 
diluted 1:100 in RPMI medium with 10% FBS and ensured proper mixing atleast 30 min at RT. 100 μl of this pre-
blocked primary antibody along with 1:200 diluted anti folate receptor antibody (positive control for the assay) were 
transferred into their appropriate wells in triplicate and incubated 1h 30min at 37o C in presence of CO2. The plates 
were washed thrice with pre warmed RPMI medium and incubated for 1hr at 37o C in presence of CO2 with 1:2000 
dilution of peroxidase-conjugated secondary antibody in RPMI medium (Polyclonal Rabbit Anti-Human 
Immunogulobulins/HRP; Dako). A triplicate negative control wells incubated with only secondary antibody was 
included thus to reduce the non specific signal from the final reading. 3 washes were performed with RPMI medium 
and once with PBS 1X. Pipette 70μl TMB/well (3,3′,5,5′-Tetramethylbenzidine liquid substrate, Sigma ) and dark 
incubate at RT  until proper intensity was observed. This TMB was transferred into a new ELISA plate already 
containing 35μl 1N H2SO4 to stop the enzymatic reaction. The absorbance at 450 nm was measured with a microplate 
reader. The cutoff value was calculated as cumulative mean + 2 (standard deviation) of the absorbance from non-
cancerous control wells. 
13.4.11 Role of Cell Surface Antigen Interacting Antibodies in Tumor Regulation by Complement Dependent 
Cytotoxicity (CDC)  
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1 × 104 OVCAR cells were seeded into each wells of 96-well tissue culture plate (Euroclone) and incubated 36 hrs at 
37 °C in presence of CO2. Once the cells were grown to confluence, culture medium was carefully removed and 
washed with 380μl/well DPBS/Ca2+/Mg2+ containing 2% BSA (Wash/blocking buffer). To measure complement 
activation by antibody, the cells were incubated with 50 µl/well of wash/blocking buffer containing individual 
antibodies purified from ascites (20 µg/ml each) for 10 minutes at 37oC. Two controls were included in this assay i) 
we used the mixture of the two antibodies cMOV18 and cMOV19 (2 µg/ml each) as well as ii) cell incubated without 
antibody. NHS (Normal Human Serum: pool of human AB Rh+ sera) was then added without washing to a final 
volume of 100 µL (ie, 1:2 solution of NHS in DPBS/Ca2+/Mg2+/2% BSA (25 µl NHS + 25 µl Wash/blocking buffer), 
and incubation was continued for further 60 minutes at 37oC. The residual viable cells were counted using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 20 µl MTT solution (5mg/ml) in 200 µl fresh 
culture medium was added to each well and incubate 4 hours at 37°C. After careful removal of culture medium, MTT 
crystals were solubilized by adding 200µl DMSO and read at 570nm with a reference wavelength set to 650nm. The 
experiment was performed in quadruplicate. 
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